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Abstract: Bacterial meningitis is a deadly disease most commonly caused by Streptococcus pneumo-
niae, leading to severe neurological sequelae including cerebral edema, seizures, stroke, and mortality
when untreated. Meningitis is initiated by the transfer of S. pneumoniae from blood to the brain across
the blood-cerebrospinal fluid barrier or the blood-brain barrier (BBB). The underlying mechanisms are
still poorly understood. Current treatment strategies include adjuvant dexamethasone for inflammation
and cerebral edema, followed by antibiotics. The success of dexamethasone is however inconclusive,
necessitating new therapies for controlling edema, the primary reason for neurological complications.
Since we have previously shown a general activation of hypoxia inducible factor (HIF-1฀) in bacterial
infections, we hypothesized that HIF-1฀, via induction of vascular endothelial growth factor (VEGF) is
involved in transmigration of pathogens across the BBB. In human, murine meningitis brain samples,
HIF-1฀ activation was observed by immunohistochemistry. S. pneumoniae infection in brain endothelial
cells (EC) resulted in in vitro upregulation of HIF-1฀/VEGF (Western blotting/qRT-PCR) associated
with increased paracellular permeability (fluorometry, impedance measurements). This was supported
by bacterial localization at cell-cell junctions in vitro and in vivo in brain ECs from mouse and humans
(confocal, super-resolution, electron microscopy, live-cell imaging). Hematogenously infected mice showed
increased permeability, S. pneumoniae deposition in the brain, along with upregulation of genes in the
HIF-1฀/VEGF pathway (RNA sequencing of brain microvessels). Inhibition of HIF-1฀ with echinomycin,
siRNA in bEnd5 cells or using primary brain ECs from HIF-1฀ knock-out mice revealed reduced endothe-
lial permeability and transmigration of S. pneumoniae. Therapeutic rescue using the HIF-1฀ inhibitor
echinomycin resulted in increased survival and improvement of BBB function in S. pneumoniae-infected
mice. We thus demonstrate paracellular migration of bacteria across BBB and a critical role for HIF-
1฀/VEGF therein and hence propose targeting this pathway to prevent BBB dysfunction and ensuing
brain damage in infections.
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Abstract
Bacterial meningitis is a deadly disease most commonly caused by Streptococcus pneumoniae, leading to severe neurological 
sequelae including cerebral edema, seizures, stroke, and mortality when untreated. Meningitis is initiated by the transfer of 
S. pneumoniae from blood to the brain across the blood–cerebrospinal fluid barrier or the blood–brain barrier (BBB). The 
underlying mechanisms are still poorly understood. Current treatment strategies include adjuvant dexamethasone for inflam-
mation and cerebral edema, followed by antibiotics. The success of dexamethasone is however inconclusive, necessitating 
new therapies for controlling edema, the primary reason for neurological complications. Since we have previously shown 
a general activation of hypoxia inducible factor (HIF-1α) in bacterial infections, we hypothesized that HIF-1α, via induc-
tion of vascular endothelial growth factor (VEGF) is involved in transmigration of pathogens across the BBB. In human, 
murine meningitis brain samples, HIF-1α activation was observed by immunohistochemistry. S. pneumoniae infection in 
brain endothelial cells (EC) resulted in in vitro upregulation of HIF-1α/VEGF (Western blotting/qRT-PCR) associated with 
increased paracellular permeability (fluorometry, impedance measurements). This was supported by bacterial localization 
at cell–cell junctions in vitro and in vivo in brain ECs from mouse and humans (confocal, super-resolution, electron micros-
copy, live-cell imaging). Hematogenously infected mice showed increased permeability, S. pneumoniae deposition in the 
brain, along with upregulation of genes in the HIF-1α/VEGF pathway (RNA sequencing of brain microvessels). Inhibition of 
HIF-1α with echinomycin, siRNA in bEnd5 cells or using primary brain ECs from HIF-1α knock-out mice revealed reduced 
endothelial permeability and transmigration of S. pneumoniae. Therapeutic rescue using the HIF-1α inhibitor echinomycin 
resulted in increased survival and improvement of BBB function in S. pneumoniae-infected mice. We thus demonstrate 
paracellular migration of bacteria across BBB and a critical role for HIF-1α/VEGF therein and hence propose targeting this 
pathway to prevent BBB dysfunction and ensuing brain damage in infections.
Keywords HIF-1α · VEGF · Dexamethasone · Meningitis · Permeability · S. pneumoniae · Blood–brain barrier (BBB) · 
Endothelium · Paracellular transmigration
Introduction
Meningitis is a life-threatening infection of the central 
nervous system (CNS). Despite advances in antimicrobial 
therapy, bacterial meningitis remains a serious threat to 
global health [54]. The most frequently detected bacterial 
species causing meningitis is S. pneumoniae, generally 
colonizing the upper respiratory tract [52, 54]. Invasive 
pneumococcal infections present mainly in young chil-
dren, the elderly and immunocompromised individuals. 
To cause bacterial meningitis, S. pneumoniae must first 
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colonize the nasopharynx to gain access to the intravas-
cular space by breaching the mucosal epithelial layer. Sur-
vival in the blood stream, translocation of the bacteria 
across of the blood–cerebrospinal fluid barrier (BCSFB) or 
the blood–brain barrier (BBB) and replication within the 
CNS ultimately cause meningitis that can lead to severe 
cerebral edema, increased intracranial pressure, seizures, 
and stroke [49]. The BBB protects and maintains homeo-
stasis in the CNS and is formed by brain microvascular 
endothelial cells (ECs) whose function is regulated by per-
icytes, astrocytes, and microglia that together with neurons 
form the neurovascular unit (NVU) [46]. Vascular damage 
has been reported as the key pathogenic process, lead-
ing to pneumococcal meningitis [22]. However, there is 
only a slight information on the pathogenic mechanism S. 
pneumoniae exploit to breach the BBB to cause meningitis 
[24]. Current treatment strategies include administration 
of high-dose antibiotics to control infection and adjuvant 
corticosteroids to reduce inflammation and alleviate BBB 
dysfunction and thereby to reduce edema. In many cases, 
controlling cerebral edema and intracranial pressure is the 
prime therapeutic goal. The beneficial effects of adjunctive 
corticosteroid therapy, primarily dexamethasone, are how-
ever inconclusive [4, 71, 22, 63]. Therefore, it is crucial to 
understand the molecular mechanisms leading to transmi-
gration of S. pneumoniae across the BBB into the CNS to 
identify novel therapeutic targets for bacterial meningitis.
S. pneumoniae shows a tropism for endothelial cells 
mediated by several pathogenicity factors. The pneumo-
coccal adherence and virulence factor A (PavA) have 
been shown to modulate adherence to host tissue, includ-
ing brain ECs [5, 56], whereas neuraminidase A (NanA), 
a surface-anchored sialidase, has been shown to con-
tribute to adherence to human brain microvascular ECs 
[69]. More recently, the essentiality of teichoic acids for 
EC adherence and virulence of S. pneumoniae has been 
reported [31]. In addition, pneumococcal adhesins (RrgA 
and PspC) have been shown to interact with the polymeric 
Ig receptor and PECAM at the BBB [34]. While these 
studies demonstrate the mechanism of bacterial adherence 
to the endothelium, the molecular pathways of the host 
endothelium involved in invasion of bacteria across the 
endothelial barrier and the route of transfer, i.e., paracel-
lular versus transcellular, are still poorly understood [18, 
60]. We have previously reported that HIF-1α activation 
is a general phenomenon in infections with subsequent 
VEGF secretion [14, 36, 75]. VEGF itself—also known 
as “vascular permeability factor” (VPF)—is responsible 
for breakdown of BBB function in, e.g., brain tumors and 
ischemic injury [23, 44, 50, 51]. Furthermore, elevated 
VEGF levels were shown in meningitis cerebrospinal fluid 
(CSF) samples [72]. We therefore hypothesized a criti-
cal role of the HIF-1α/VEGF signaling in the migration 
of S. pneumoniae across the BBB subsequently causing 
meningitis.
To investigate the role of HIF-1α/VEGF pathway in 
migration of S. pneumoniae across the BBB, we analyzed 
mouse and human meningitis specimen for HIF-1α activa-
tion. Infection of brain ECs with S. pneumoniae followed by 
HIF-1α/VEGF expression and EC permeability was assessed 
in vitro. To elaborate the route of bacterial translocation 
across the endothelium, localization of S. pneumoniae was 
assessed by confocal, super-resolution and live-cell imaging 
in brain ECs. To analyze the mechanisms of S. pneumoniae 
transfer in vivo, permeability analysis and bacterial pres-
ence were assessed, followed by electron microscopy of 
hematogenously infected mice. Isolated brain microvessels 
from infected mice were subjected to RNA sequencing to 
assess regulation of the HIF-1α/VEGF pathway. The con-
tribution of HIF-1α on S. pneumoniae-induced permeability 
was analyzed in loss-of-function (LOF) experiments using 
HIF-1α inhibitor echinomycin and in brain ECs from HIF-1α 
KO mice. Finally, therapeutic rescue experiments were 
performed using echinomycin in S. pneumoniae-infected 




Adult (3–6 months old) wild-type C57BL/6 mice of both 
sexes were used in the study unless otherwise specified. 
Transgenic HIF-1αflox/flox mice of the same age group were 
also used post-PCR validation of the genotype [62]. The 
number of animals and number of experiments are indi-
cated where appropriate. All animals were sacrificed under 
anesthesia and their number was kept to a minimum based 
on extracted tissue/cell amount and based on statistically 
appropriate sample size. Mice were handled according to the 
German Protection of Animals Act and in compliance with 
ARRIVE (animal research: reporting of in vivo experiments) 
guidelines and principles of laboratory animal care (NIH 
publication No. 86-23, revised 1985). The local committee 
regulations were strictly followed for the approved animal 
experiments (Approval # 33.9.42502-04-14/1553 by the 
Animal Ethics Committee of Lower Saxony State Office for 
Consumer Protection and Food Safety (LAVES) to R. Nau 
and approval # 55.2-1-54-2532-78-2012 by the Committee 
on the Ethics of Animal Experiments of the Government of 
Upper Bavaria to U. Koedel).
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Human meningitis specimen
All the studies on human subjects were approved by an eth-
ics statement (GS-249/11 for autopsy material and GS-04/09 
for resection material, to K. Plate, Goethe University Hospi-
tal, Frankfurt, Germany). Tissue was formalin fixed, paraffin 
embedded and utilized in immunohistochemistry analysis. 
Relevant anonymized patient data are included in Table 1.
Immunohistochemistry from mouse/human 
meningitis samples
Formalin-fixed paraffin-embedded mouse meningitis sam-
ples and autopsy samples from human meningitis cases 
(including bacterial, viral, fungal or parasitic meningitis 
infections) were collected to investigate HIF-1α activation 
by immunohistochemistry. In brief, paraffin-embedded 
samples were cut into 3–5 µm thin sections on a Leica 
microtome (SM2000R, Leica Microsystems, Germany) 
and were deparaffinized and rehydrated in decreasing 
ethanol concentration prior to different stainings. Hema-
toxylin and eosin (H & E) stainings were used for the 
histopathological examination and diagnostics. Single or 
double stainings using various antibodies (Table 2) were 
performed by standard protocols on a Ventana Discov-
ery XT automated immunohistochemistry system (Roche, 
Switzerland).
Table 1  Quantification 
and patient data of human 
meningitis cases
Ten areas in the cortex and five in the leptomeninges were counted for HIF-1α-positive cells from each 
specimen in five pneumococcal meningitis cases. The patient data for these cases and other cases of men-
ingitis examined (supplementary Fig. 2, online resource) are included. NA indicates data not available and 
NC indicates not counted. For some cases, the staining signal was weak (indicated by +). Cause of death 
for all the patients from (1–8) was meningitis, but for patient 9 it is not available
Case Id Age Gender Meningitis pathogen Number of HIF-1α + cells Signal
Cortex Leptomeninges
1 64 Male S. pneumoniae 0 0
2 61 Male S. pneumoniae 35 650  +++ 
3 88 NA S. pneumoniae 23 30  + 
4 63 Male S. pneumoniae 150 88  ++ 
5 24 Male S. pneumoniae NC NC  ++ 
6 71 Male M. tuberculosis NC NC  ++ to +++ 
7 67 Female Fungi NC NC  ++ to +++ 
8 72 Male T. gondii NC NC  ++ to +++ 
9 28 Female C. neoformans NC NC  ++ to +++ 
Table 2  Antibodies used for 
Western blotting (WB) and 
immunohistochemistry (IHC)
Antibody Application Company Reference Dilution
α-Tubulin (mouse) WB Sigma-Aldrich T6199 1:500
β-Actin (mouse) WB Santa Cruz sc-69879 1:500
VE-cadherin (goat) WB/IHC Santa Cruz sc-6458 1:200
Claudin-5 (mouse) WB/IHC Invitrogen 352500 1:200
CD31 (rat) IHC Dianova DIA310 1:50
Occludin (mouse) IHC Invitrogen 331500 1:200
ZO-1 (rabbit) IHC Invitrogen 617300 1:200
Podocalyxin (goat) IHC R&D Systems AF1556 1:200
HIF-1α (rabbit) WB/IHC Novus Biologicals NB100-134 1:200
Pneumococcal (rabbit) IHC Dr. Hammerschmidt NA 1:500
Donkey anti-goat 555 IHC ThermoFisher SA5-10087 1:500
Donkey anti-rabbit 488 IHC ThermoFisher SA5-10038 1:500
Donkey anti-mouse 555 IHC ThermoFisher SA5-10167 1:500
Donkey anti-mouse 680 WB LI-COR 925-68072 1:2000
Donkey anti-rabbit 800 WB LI-COR 925-32213 1:2000
Donkey anti-goat 800 WB LI-COR 925-32214 1:2000
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Bacterial strains and culture conditions
S. pneumoniae serotype 2 strains D39 (NCTC 7466), 
D39Δcps, HlpA-GFP-cat modified D39 strain ([40], and 
serotype 4 strains TIGR4 and TIGR4Δcps were used as 
described previously [58, 75]. Frozen vials of S. pneumoniae 
were thawed and cultured on Columbia blood agar plates 
(Oxoid, 5% sheep blood) for 8–10 h at 37 °C and passaged 
for 12–14 h. S. pneumoniae from blood agar plate were resus-
pended in Todd–Hewitt broth (Oxoid, UK) supplemented with 
0.5% yeast extract (THY) to mid-log phase for use in infec-
tion experiments. Growth rates were quantified by measuring 
optical density (NanoPhotometer® P-Class, Implen, Germany) 
and by counting colony forming units (CFU) [56].
Culture of bEnd5 cells
Immortalized mouse brain endothelioma cells (bEnd5 [61]) 
were grown in DMEM (GlutaMAX™, high glucose, pyru-
vate containing media, Gibco, Germany) supplemented with 
10% FBS (Sigma, Germany), β-mercaptoethanol (75 µM), 
1% nonessential amino acids, 100  U/ml penicillin and 
100 µg/ml streptomycin, in a humidified incubator at 37 ºC 
with 5%  CO2. T75 flasks were coated with gelatin solution 
(0.1%) for 1 h at 37 ºC and bEnd5 cells were plated at a 
density of 25,000/cm2 and passaged after 7–8 days by 0.05% 
trypsin/EDTA treatment with media change every 2–3 days.
Isolation and culture of primary mouse/human 
brain microvascular ECs
Primary mouse brain microvascular endothelial cells 
(MBMECs) were isolated from adult WT C57BL/6 or 
HIF-1αflox/flox mice and cultured exactly as described pre-
viously [27]. Cultures were maintained in MCDB-131 
complete medium (MCDB-131 (Gibco, Germany), 2 mM 
L-glutamine (Gibco), 20% FBS (Biochrom), 0.01% heparin 
(Sigma), 2 mM penicillin–streptomycin solution (Gibco), 
0.1%  NaHCO3 and 0.05 mg/ml endothelial cell-growth sup-
plement ECGS (lyophilized powder prepared from homog-
enized porcine brains obtained from slaughterhouse [2]). 
Preparations were quality controlled by spindle morphology 
of ECs and by immunocytochemistry for EC markers (clau-
din-5, VE-cadherin) [13]. Primary human brain microvas-
cular endothelial cells (HBMECs) were obtained at passage 
2 (Pelobiotech, Germany) and cultured as described above 
for MBMECs and used within passage #5.
Culture of primary human pericytes and primary 
mouse astroctyes
Primary human pericytes (passage #5–8, ScienCell, USA) 
and primary mouse astrocytes (isolated from pups as 
described previously [27, 70], passage #1–2) were cultured 
in their respective media (pericyte medium, ScienCell) or 
astrocyte medium comprising DMEM (high glucose, Glu-
taMAX™, pyruvate, Gibco®), 10% FBS, 100 U/ml penicil-
lin and 100 µg/ml streptomycin.
Detection of cellular hypoxia in vitro
Cellular hypoxia was investigated in bEnd5 cells upon 
S. pneumoniae infection using the hypoxia-sensitive marker 
pimonidazole hydrochloride (Hypoxyprobe™ Red549 kit, 
Hypoxyprobe, USA). Cellular hypoxia was detected by 
adding 200 mM pimonidazole hydrochloride to bEnd5 cells 
30 min prior to infection. Pimonidazole–protein adducts 
formed (proportional to level of hypoxia) were detected by 
immunofluorescence staining according to the manufac-
turer’s protocol.
Oxygen measurement assay in vitro
The  O2 concentration in the culture medium of infected 
bEnd5 cells was measured using the SensorDish® reader 
(SDR, Germany). Cells were directly seeded on the OxoD-
ish® (OD) 24-well polystyrene dish. Upon infection, the 
dish was placed over the SDR and equilibrated to  CO2 (5%) 
and  O2 (19%) levels set within a tissue-culture incubator 
at 37 °C. Pre-calibrated oxygen sensors integrated at the 
bottom of each well allow for non-invasive contactless read-
out in the SDR through the transparent OD plate bottom. 
Oxygen level was equilibrated for 1 min at 37 °C, followed 
by measurement every 5 min up to 3 h post-infection and 
 O2 concentration in the medium was obtained  (pO2% air 
saturation).
Western blotting
Culture (6–7 days) and infection of bEnd5 cells were per-
formed in six-well plates as described above. At the end 
point, cells were washed in ice-cold PBS, followed by 
harvesting them in HEPES EDTA sucrose buffer (HES, 
10:1:250 mM, pH 7.4) containing protease and phosphatase 
inhibitors. Western blotting was performed as described pre-
viously with a few modifications [12, 13]. Cell suspensions 
in HES were sonicated and aliquoted for western blotting 
and protein assay and stored at − 80 °C until use. Protein 
concentration was measured by BCA assay (Thermo Fisher) 
and equal amounts of proteins were solubilized (2.3 M urea, 
1.5% SDS, 50 mM Tris, 25 mM TCEP and 0.01% BPB) for 
1 h at 30 °C on a shaker and centrifuged at 15000×g for 
5 min at RT to remove insoluble debris. Equal volumes of 
solubilized supernatants were loaded onto 8–12% Tris–HCL 
bis-acrylamide gels and subjected to electrophoresis (80 V, 
3 h, RT). The gels were subsequently transferred overnight in 
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Tris–glycine buffer containing 20% methanol without SDS 
(8 °C, 36 V). The membranes were subjected to Ponceau 
staining to confirm transfer and equal loading of proteins. 
The membranes were then blocked (1 h, RT), followed by 
primary antibody incubation overnight (8 °C) in 1 × Roti®-
block buffer (Roth). The washed membranes (3 × 5 min in 
0.1% Tween/PBS) were subjected to secondary antibody 
incubation in the same buffer, rinsed in PBS and imaged by 
Odyssey Fc imager (Li-COR). The acquired images were 
analyzed with Image Studio 2.1 (Li-COR). Quantification 
of pixel intensity was performed from equal-area rectan-
gles drawn around bands of interest (subtracting background 
from an empty lane), normalizing to the values of β-actin 
(housekeeping protein) and presented as percentage of con-
trol. Antibodies used and their dilutions are included in the 
Table 2.
Quantitative RT‑PCRs
Samples taken from the in vitro permeability assays were 
used for qRT-PCR for direct comparison to functional data. 
Total RNA was extracted using RNeasy micro or mini kit 
including RNase-free DNase set (Qiagen, Germany) for 
inhibiting residual DNase activity. The cDNA was gener-
ated using RevertAid H-Minus First Strand cDNA synthesis 
kit (ThermoScientific, Germany) according to the manufac-
turer’s protocol. Quantitative RT-PCR was performed using 
ABsolute qPCR SYBR Green Fluorescein Mix (Thermo Sci-
entific, Germany) in a LightCycler® 480 Real-Time PCR 
Detection System (Roche, Germany) using the following 
conditions: 15 min at 95 ºC, 45 cycles of (30 s at 95 ºC, 
30 s at 61 ºC, and 35 s at 72 ºC), 1 min at 95 ºC, 1 min 
61 ºC, and for melt curves 80 cycles at a set point of 55 ºC 
with 0.5 ºC step and 94.5 ºC exit temperature. LightCycler® 
480 instrument software version 1.5 (Roche, Switzerland) 
was used for analyzing the RT-PCR data and exported into 
Excel (Microsoft Office, USA) for quantification of expres-
sion values (R) according to  2−∆∆Ct method using RPLP0 
and G6PDX as housekeeping genes. Primers were designed 
using primer3 software (https ://bioin fo.ut.ee/prime r3-0.4.0/) 
from mouse or human mRNA refseq ID from NCBI and 
validated in efficiency curves before use. Primers sequences 
are included in Table 3.
Dextran‑based transwell permeability assay in BBB 
infection models
Cells (bEnd5, MBMEC or HBMEC) were grown in tran-
swell chambers (Fig. 3a) as described earlier with slight 
modifications [8, 27]. Approximately 100,000 cells/cm2 
were seeded on fibronectin- (5 µg/cm2, Sigma Aldrich, 
Germany) coated 24-well plate cell-culture inserts (PET 
1.0 micron, Greiner Bio-one, Germany) and cultured in 
antibiotic-free complete medium (described above for the 
particular cell type) for 3–4 days for primary brain ECs and 
5–6 days for bEnd5. Bacteria were thawed (S. pneumoniae 
D39 and TIGR4 strains) and centrifuged at 2500×g for 5 min 
at room temperature, washed with PBS and re-suspended 
in the infection medium (antibiotic-free complete medium 
containing 1% FBS). Dextrans (3 kD tetramethylrhodamine 
(TMR)/70 kD fluorescein isothiocyanate (FITC, Ther-
moFisher) were added to the infection medium (10 µM) and 
cells infected apically for 3–6 h at multiplicity of infection 
(MOI) of 50 in a total volume of 200 µl, whereas the basal 
chamber contained 600 µl of the infection medium. Media 
aliquots (100 µl) were collected at designated time points 
and twofold 100% ethanol was added to kill bacteria and 
200 µl was transferred to black-well plates (Greiner Bio-
One, Germany) for dextran permeability assessment. The 
following excitation/emission (nm) was utilized for reading 
the fluorescence: TMR 3 kD dextran (550/580), followed by 
FITC 70 kD dextran (490/520) in Infinite M-200 PRO fluo-
rescence plate reader (Tecan). For permeability assessment, 
the raw fluorescence units (RFU) obtained for the bottom 
chamber were normalized to the top chamber and expressed 
as percentage relative to control condition as described pre-
viously [8].
Dextran‑based transwell permeability assays using 
conditioned media
Primary human pericytes and primary mouse astrocytes 
were cultured until confluency and infected with S. pneumo-
niae (MOI 50, 3 h). The media supernatant along with bac-
teria was collected, filtered (0.2 µm) and stored at − 80 °C. 
The influence of pneumococcal infections of astrocytes and 
pericytes on the endothelial barrier was assessed by treat-
ment of bEnd5 cells plated on inserts with the conditioned 
media (diluted 1:3 with fresh medium). Permeability assays 
were performed as described above.
Transendothelial electric resistance (TEER) 
measurements
Transwell inserts (1 µm-pore 24-well PET) were coated with 
fibronectin and bEnd5 cells (100,000/cm2) were seeded and 
transferred to a cellZscope® device (NanoAnalytics, USA) 
Table 3  Mouse-specific primers used for qRT-PCR analysis
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placed in a humidified incubator (37 °C, 5%  CO2). TEER 
values were obtained from continuous impedance meas-
urements as described previously [8]. Once a plateau was 
reached in TEER levels (typically after 4–5 days), cells were 
infected with D39 (MOI: 100) in the infection medium as 
described above and TEER measurements were obtained for 
8 h post-infection. TEER data were obtained in ohm cm2, 
followed by setting the value of the control group between 
3–4 h post-infection to 100% within the cellZscope software 
(v2.2) for ease of analysis. These data and representative 
images were exported for subsequent analysis.
Bacterial transmigration assays
Infection of bEnd5 cells was performed exactly as described 
above for permeability assays (Fig. 3a, b), but using 3.0 µm 
pore inserts to allow bacterial transmigration. Media col-
lected from the bottom chamber of duplicate wells (1.2 ml) 
were pooled, centrifuged (3000×g, 10 min, RT) and resus-
pended in 100 µl of DMEM infection media without antibi-
otics. Serial dilutions  (100–105) of the bacterial suspension 
were plated in triplicate on blood agar plates and incubated 
at 37 °C overnight. Aliquots from inserts were also plated 
as a control for the assay. Quantification of microorganisms 
was performed by visually counting the number of CFU in 
each dish and expressed as  log10 CFU/ml.
Immunofluorescence staining of cultured brain ECs
Primary mouse brain ECs (MBMEC) or bEnd5 cells on 
inserts were washed twice with cold 1×PBS and fixed with 
− 20 °C cold methanol for 3 min at RT, followed by a PBS 
wash. Fixed cells on inserts were then blocked and permea-
bilized for 45 min at RT in PBS containing 1% BSA and 
0.5% Triton X-100, pH 7.5. Primary antibody staining was 
performed for 1 h at RT in the antibody incubation buffer 
(PBS containing 0.5% BSA, 0.25% Triton X-100, pH 7.2), 
followed by 3 × 5 min washes in PBS. Species-specific fluo-
rescent secondary antibodies were used in combination with 
DAPI (0.3 µM) and incubated for 1 h at RT, followed by 
washes in PBS (3 × 5 min). Inserts were then cut out and 
mounted on glass slides using Fluroprep (bioMérieux, Ger-
many) or Aqua-Polymount (Polysciences Inc., Germany). 
Slides were kept for drying overnight at RT in dark, fol-
lowed by visualization and image acquisition using a wide-
field microscope (Nikon 80i) or a confocal fluorescence 
microscope (Nikon C1si). The same procedure was also 
performed for MBMECs or HBMECs that were cultured in 
fibronectin-(5 µg/cm2) coated chamber slides (8-well, cover 
glass II, Sarstedt) suitable for super-resolution microscopy 
(SRM) and imaged directly in PBS after staining using 
Nikon N-SIM microscope (Nikon Apo TIRF 100× objective, 
Germany) for SRM or Nikon C1si for confocal imaging. 
Images were processed using NIS Elements imaging soft-
ware (version 4, Nikon) and saved in the raw ND2 format 
and exported as TIFF files. Antibodies and their dilutions 
are included in Table 2.
Immunofluorescence staining and quantification 
for paraffin‑embedded brain tissues
PFA (4%) fixed paraffin-embedded brain sections (3–5 µm) 
were also subjected to immunofluorescence staining after 
standard deparaffinization protocol. Epitope retrieval was 
performed for 45 min in boiling citrate buffer (1 × AR6, 
PerkinElmer). After cooling down for 30 min at RT, slides 
were washed with PBS, followed by blocking/permeabiliza-
tion in PBS containing 0.5% BSA and 0.2% Triton X-100, 
pH 7.4. Sections were encircled with a PAP pen to create 
a hydrophobic barrier, followed by adding 70–80 µl of the 
primary antibody mix and slides incubated O/N at 4 °C in 
a humidified chamber. After three washes, 5 min each in 
PBS/0.2% Triton, species-specific fluorescent secondary 
antibody mix containing DAPI (1:500) was added and the 
slides incubated for 1 h at RT. After two washes in the above 
wash buffer, two final washes were performed in PBS fol-
lowed by mounting the slides with Aqua Polymount (Poly-
sciences Inc.) and allowed to dry at least O/N in dark at RT 
before proceeding to microscopy. Antibodies and their dilu-
tions are included in Table 2. Images were acquired using a 
wide-field microscope (Nikon 80i) using 60× water immer-
sion objective with set exposure and gain settings across 
samples for a particular antibody combination. For the pur-
pose of quantification of expression intensity, four images 
were obtained for each animal for a particular antibody 
staining, utilizing two sections and acquiring two images/
section from frontal and occipital cortical regions. Using 
the NIS-Elements software (version 5, Nikon), the acquired 
raw ND2 image files were subjected to binary thresholding 
using whole image as the region of interest (ROI). Measure-
ment was then performed for binary area, mean fluorescence 
intensity, and number of objects applying 1 × clean function, 
4 × separation as well as size range of 3–9 µm for objects. 
Colocalization analysis was performed from overlapping 
binary area between corresponding channels using inter-
section function in the software. All binary layers including 
intersection layers were stored within the original ND2 files. 
Values from each of the four images for an animal per anti-
body combination for all channels including co-localization 
were exported to a spreadsheet (MS Office Excel). Immuno-
histochemistry (IHC) expression intensity was obtained in 
arbitrary units (a.u) as the product of thresholded binary area 
and the mean fluorescence intensity. IHC cell number was 
obtained as the number of objects in the thresholded image. 
Co-localization IHC intensity was obtained as the product 
of overlapping binary area between channels with the mean 
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intensity of channel of interest. The same intersection analy-
sis also yielded the number of co-localized objects. Data 
were organized in the spreadsheet such that a row repre-
sented animal ID and replicates from the four images were in 
four adjacent columns. This data was then imported to Prism 
software (v5, GraphPad) into a grouped data table with four 
sub-replicate columns followed by graphing and statistical 
analysis comparing two groups at a time. For representative 
images, confocal laser scanning microscopy (Nikon C1si) 
was performed using either 60× or 100× objective (zoom 
factor 2 for scanning) and images exported as high-resolu-
tion TIFF files.
Live‑cell imaging of S. pneumoniae‑infected brain 
ECs
Primary brain microvascular ECs (MBMEC) were iso-
lated from three adult wild-type mice and plated directly 
on an eight-well chamber slide with glass bottom (Ibidi) 
precoated with rat-tail collagen (Corning) as described for 
MBMEC isolation. ECs from each animal were plated onto 
two wells with a growth area of 1 sq cm per well. After 4 h, 
the medium was changed to puromycin containing MCDB-
131 complete medium as described in the MBMEC isolation 
and cultured for 2 days. On day 3, cells were infected with 
GFP-labeled D39 S. pneumoniae strain [40] at an MOI of 10 
using 20 µl of 5 × 106 CFU/ml bacteria in 0.3 ml media per 
well. Live-cell imaging was initiated 1 h post-infection on a 
Nikon Eclipse Ti microscope fitted with an incubation cham-
ber attached to temperature and  CO2 controllers (Okolab). 
The temperature was maintained at 37 °C by a heated water 
bath (E200, Lauda) attached to its controller. The  CO2 level 
was maintained at 5% by its controller attached to a bubbler 
installed in the water bath mixed with  CO2 from an external 
tank utilizing an air pump (Okolab). Images were acquired 
using DS-Qi2 camera (Nikon) at 10 s intervals simultane-
ously in bright field and GFP fluorescence channels for a 
duration of 2 h using 40× Plan Apo objective, setting an 
additional 1.5× zoom on the microscope for all lenses to 
obtain a total 60× magnification. The saved raw ND2 files 
were processed in NIS-Elements software (version 5, Nikon) 
for regions/time intervals of interest and exported as TIFF 
image files and MP4 format video files.
Murine infection models and downstream 
processing
Three mouse pneumococcal infection models—infection via 
intracerebral, intracisternal and via intraperitoneal routes—
were utilized in this study. For intracerebral infection, mice 
received 10 µl of  105 CFU/ml of S. pneumoniae D39 after 
i.p anesthesia with ketamine (100 mg/kg) and xylazine 
(10 mg/kg) as described previously [32]. For intracisternal 
infection, 15 µl of  107 CFU/ml of S. pneumoniae D39 strain 
was injected under brief anesthesia with isofluorane [6]. 
Animals were sacrificed between 24 and 48 h post-infection 
and brains were extracted and formalin fixed, followed by 
embedding in paraffin for use in immunohistochemistry. 
Hematogenous infection was induced by intraperitoneal 
injection of 100 µl of  107 CFU/ml S. pneumoniae D39 strain 
[68, 74]. Animals were anesthetized 18 h post-infection, fol-
lowed by transcardial perfusion with PBS as described pre-
viously [15] and used in permeability assay, EM analysis or 
for brain microvessels isolation [27].
In vivo tracer permeability assay
Permeability assays were performed as described previously 
[15] in infected or healthy animals (Fig. 4a). TMR 3kD dex-
tran (200 µl of 2 mM stock in PBS, D3308, Thermo Fisher, 
Germany) was injected intraperitoneally, followed by anes-
thesia 5 min later. After a circulation time of 20 min for the 
tracer, the animals were prepared for transcardial perfusion 
and ~ 300 µl blood was collected from the chest cavity just 
after atrial puncture, followed by perfusion for 3 min with 
PBS. Hemibrain (free of the olfactory lobes, cerebellum and 
hindbrain) and a single kidney were collected and immedi-
ately frozen on dry ice and stored at − 80 °C. For fluores-
cence measurement, samples were thawed on ice, weighed 
and homogenized in PBS (200 µl for hemi-cerebrum and 
300 µl for kidney), followed by centrifugation for 20 min, 
4 °C at 15,000×g. Supernatants (40 µl) as well as equal 
volumes of serum (1/5 dilution in PBS) were loaded into a 
384-well black plate and fluorescence was measured at the 
corresponding excitation (550 nm)/emission (580 nm) in a 
plate reader (Tecan, Switzerland). Sham animals (without 
tracer injection) were used to subtract autofluorescence val-
ues. Permeability index (ml/g) was calculated as the ratio of 
(tissue RFUs/g tissue weight) to (serum RFUs/ml serum).
Transmission electron microscopy of brain tissues 
of S. pneumoniae‑infected mice
Animals were subjected to intraperitoneal S. pneumoniae 
infection for 18 h, followed by anesthesia and transcar-
dial perfusion with PBS (2 min) and then with 4% PFA/
PBS (4 min). The isolated brains were post-fixed with 4% 
PFA/2% glutaraldehyde overnight at 4 °C. The tissue was cut 
into small pieces and post-fixed with 1% OsO4 for 2 h at RT, 
dehydrated in graded acetone and embedded in Durcupan 
with the polymerization for 72 h at 60 °C. Ultrathin sections 
were cut (Leica Ultracut UCT, USA), contrast enhanced 
with lead citrate and uranyl acetate and analyzed using Tec-
nai Spirit BioTWIN (FEI, ThermoFisher, Germany) elec-
tron microscope at 120 kV. Images were acquired with an 
Eagle 4 K CCD bottom-mount camera (FEI, ThermoFisher, 
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Germany). Artificial coloration was performed using Pho-
toshop CS4 (Adobe).
Isolation of mouse brain microvessels (MBMVs)
Mice with and without intraperitoneal S. pneumoniae infec-
tion were anesthetized, followed by transcardial perfusion of 
PBS as described previously [74]. Brain microvessels were 
isolated as described previously [12, 13, 27]. Brains were 
harvested and cerebellum and olfactory lobes were removed, 
followed by rolling on Whatman filter paper (Schleicher & 
Schuell, Germany) to peel off meninges. The pooled cer-
ebral hemispheres were homogenized in microvessel buffer 
(MVB, 15 mM HEPES, 147 mM NaCl, 4 mM KCl, 3 mM 
 CaCl2, 1.2 mM  MgCl2, 5 mM glucose, and 0.5% BSA, pH 
7.4) applying 15–20 strokes using a Dounce homogenizer 
(0.025 mm clearance, Wheaton, USA) attached to an over-
head electric stirrer (2000 RPM, 45 W, VOS14, VWR). 
Samples were then centrifuged at 400×g for 10 min at 4 °C 
and the pellet was resuspended in fourfold 25% BSA in PBS 
and further centrifuged at 2000×g for 30 min to remove 
myelin fat that was aspirated carefully. The microvessel pel-
let containing red cells and nuclei was resuspended in MVB 
and filtered through 100-μm and 40-μm nylon meshes (Bec-
ton Dickinson, Germany). Microvessels on top of the 40-μm 
mesh were washed in MVB and lysed directly on mesh with 
RLT buffer (Qiagen, Germany) containing 40 mM dithi-
othreitol (DTT) and stored at − 80 °C until use. The scheme 
for the isolation is included (Fig. 6a).
RNA sequencing of brain microvessels from mice 
infected with S. pneumoniae
RNA was isolated from brain microvessels from healthy and 
intraperitoneally infected mice using the RNAeasy micro 
Kit (Qiagen, Germany) including a DNase digestion step 
to eliminate genomic DNA. The quality of RNA and the 
prepared library was verified on LabChip Gx Touch 24 (Per-
kin Elmer, Germany). Equal amount of total RNA (200 ng), 
measured by Qubit 3.0 (ThermoFisher, Germany) was used 
as input for SMARTer Stranded Total RNA Sample Prep 
Kit—HI Mammalian (Clontech, USA). Sequencing was 
performed using v2 chemistry (NextSeq500 instrument 
(Illumina, USA), resulting in an average of 28 million reads 
per library (1 × 75 bp single-end setup) that were assessed 
for quality, adapter content and duplication rates (FastQC: 
a tool for high throughput sequence data—https ://www.
bioin forma tics.babra ham.ac.uk/proje cts/fastq c). Reaper 
version 13–100 was employed to trim reads after a qual-
ity drop below a mean of Q20 in a window of 10 nucleo-
tides [9], utilizing reads between 30 and 150 nucleotides for 
further analyses. Trimmed and filtered reads were aligned 
with the Ensembl mouse genome version mm10 (GRCm38) 
using STAR 2.4.0a [17] with the parameter “–outFilterMis-
matchNoverLmax 0.1” to increase the maximum ratio of 
mismatches to mapped length to 10%. The number of reads 
aligning to genes was obtained from the Subread pack-
age using featureCounts 1.4.5-p1 tool [45], aggregating 
per gene only those reads mapping at least partially inside 
exons, whereas those overlapping multiple genes or to mul-
tiple regions were excluded. Differentially expressed genes 
were identified using DESeq2 version 1.62 [48], and genes 
with a minimum fold change of ± 1.5 (log2 ± 0.59), a maxi-
mum Benjamini–Hochberg corrected p value of 0.05, and 
a minimum combined mean of five reads were considered 
significant for differential expression. Based on the gene 
identifiers, the Ensemble annotation was enriched with 
UniProt data (release 06.06.2014). Bioinformatics analy-
ses were performed for enriched pathways and diseases on 
genes commonly regulated in all four meningitis microves-
sel samples compared to all the healthy ones (p < 0.05, log 
twofold-change > 0.585). KOBAS web server including 
KEGG, PANTHER, and Reactome databases [76] was used 
for these analyses.
Loss‑of‑function (LOF) experiments for HIF‑1α
Echinomycin (Calbiochem, Germany), a chemical inhibi-
tor of HIF-1α, was used to treat bEnd5 cells at concentra-
tion of 100 nM in complete medium 24 h prior to infec-
tion, followed by permeability assays. Genetic knockdown 
experiments were performed in bEnd5 cells using siRNA 
for HIF-1α. Cells were first plated onto inserts as described 
for transwell permeability assay, followed by transfection 
with HIF-1α siRNA on the next day using Lipofectamine 
RNAiMax. To 0.5 ml of OptiMEM medium (ThermoFisher, 
Germany), 10 µl (10 µM stock) each of the two siRNAs 
(Qiagen SI00193011, SI00193018) were added and to 
another tube containing 0.5  ml OptiMEM 10  µl Lipo-
fectamine RNAiMax (ThermoFisher, Germany) was added. 
After mixing both tubes individually, they were incubated 
for 5 min at RT, followed by combining the two tubes and 
incubation for another 15 min at RT. During the incuba-
tion time, cells were washed once with OptiMEM medium 
and 200 µl of fresh OptiMEM was added to each insert and 
1 ml was added to the bottom chamber. After the incuba-
tion of the siRNA mix, 100 µl was added to each insert and 
the medium changed to bEnd5 complete medium after 6 h. 
Infection and permeability/qRT-PCR assays were performed 
3 days after transfection as described earlier.
HIF-1α KO in primary mouse brain microvascular ECs 
was performed as shown in the schematic of Fig. 7d. Briefly, 
MBMECs were isolated from HIF-1αflox/flox mice. After over-
night culture, cells were treated with puromycin (5 µg/ml) 
for 2 days to obtain pure ECs, as puromycin is toxic to non-
ECs. The pure MBMECs from HIF-1αflox/flox mice were then 
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treated with TAT-cre (1 µM, Excellgen, USA) for 2 days in 
antibiotic-free MCDB-131 complete medium. Cells were then 
split on to transwell inserts at passage 1 and were used 2 days 
post-plating for infection and permeability/qRT-PCR assays 
as described earlier.
Therapeutic rescue experiments
Adult wild-type female mice were infected with S. pneumo-
niae D39 strain by intraperitoneal (i.p.) injection of 100 µl 
of 5 × 106 CFU/ml bacteria [68, 74]. Animals were treated 
with echinomycin (20 µg/kg body weight) by i.p. injection 
every 12 h starting 4 h post-infection using a 5 µM stock 
(5%DMSO/95% PBS, 100 µl/20 g mouse). Control animals 
were injected with 100 µl of just the vehicle (5% DMSO/95% 
PBS). Clinical scoring was performed in a blinded fashion 
every 4 h starting 16 h post-infection on a 4-point scale with 
1 being the lowest score and 4 highest score indicating severe 
symptoms as described previously [29]. Animals that had 
a clinical score of 3 or more indicating severe lethargy and 
impaired mobility were euthanized and the ones that died in 
between the scoring time points were given the worst score of 
4. This therapeutic survival experiment was conducted for a 
total duration of 48 h at which time point all surviving animals 
were sacrificed. Irrespective of the treatment group, at the sur-
vival end point, i.e., when the animal died or at the end point 
of the experiment, i.e., 48 h, the brain was harvested, split at 
the miline with one hemi-brain stored in 4% PFA on ice and 
the other hemi-brain embedded natively in O.C.T compound 
on dry ice. The PFA tissue was fixed O/N at 4 °C, followed by 
paraffin embedding using standard protocols and the blocks 
stored at room temperature for use in immunohistochemis-
try (IHC). The natively embedded material was transferred to 
−80 °C for use in cryo IHC. Analysis was performed for over-
all survival (OS) based on the total time the animal survived 
post-infection and for progression-free survival (PFS) based 
on time post-infection until the first symptoms indicated by a 
clinical score of 1.
Statistical analysis
Statistics were performed using Prism 5.0/6.0 software 
(GraphPad, USA). A p value < 0.05 was considered significant. 
Data in graphs are represented as mean ± SEM with *p < 0.05; 
**p < 0.01; ***p < 0.001. The number of animals and experi-
mental repeats are indicated in the corresponding figure leg-
ends including the statistical test employed.
Results
HIF‑1α activation in neural cells in mouse 
and human pneumococcal meningitis
HIF-1α activation is a general phenomenon upon infec-
tions [36, 75], and elevated VEGF levels known to be 
regulated via HIF-1α were found in CSF of meningitis 
patients [72]. To investigate the involvement of HIF-1α/
VEGF pathway in the course of pneumococcal meningitis, 
we analyzed mouse and human brain specimen by HIF-1α 
immunohistochemistry (IHC). Murine pneumococcal 
meningitis was induced by intracerebral or intracisternal 
injection of S. pneumoniae (0.9% sterile NaCl for control 
animals) as described previously [32, 42]. By 24 h post-
inoculation, all mice presented clinical signs of infection 
such as hypothermia, reduced vigilance, impaired motor 
function and weight loss. Mice were sacrificed at differ-
ent time points and the brain tissue was immediately fixed 
in PFA and embedded in paraffin. 36 h post-intracerebral 
infection, granulocyte infiltrates were detected by hema-
toxylin/eosin staining in the ventricle and the white matter 
of the infected hemisphere, but not in the contralateral 
uninfected hemisphere (data not shown). At this time 
point, staining for HIF-1α was positive in the white matter 
and the surrounding cortex region with the typical nuclear 
staining pattern that indicated HIF-1α activation in the 
neural cells in the intracerebrally infected mice (Fig. 1a, 
b). The contralateral hemisphere did not show any sign 
of infection and HIF-1α staining was mostly cytoplasmic, 
excluding HIF-1α activation (Fig. 1c). Nuclear HIF-1α 
was also visible at 24 h post-infection in the cortex region 
in the intracerebral model (Fig. 1d) that was also con-
firmed at 48 h post-infection in an intracisternal infection 
model (Fig. 1e, f), in which the control vehicle injected 
mice did not show any specific HIF-1α staining. Similar 
findings were observed in human pneumococcal menin-
gitis samples (Fig. 1 g-j, Table 1). Staining for HIF-1α 
showed nuclear signal in leukocytes of the inflammatory 
infiltrate layer and in some astrocytes of edematous brain 
parenchyma double labeled with HIF-1α/GFAP (Fig. 1g). 
Macrophages, however, showed non-specific cytoplasmic 
signal indicating no HIF-1α activation. MAP2-stained 
neurons were also positive for nuclear HIF-1α but mostly 
the pyknotic neurons (Fig. 1h), which was also observed in 
the cells associated with small vessels in the cortex region 
(Fig. 1i). Double immunofluorescence staining for HIF-1α 
with CD31 as an endothelial marker also showed positive 
nuclei in ECs from three independent cases, indicating 
HIF-1α activation in brain ECs upon pneumococcal men-
ingitis (Fig. 1j, supplementary Fig. 1, online resource). 
Activation of HIF-1α was also observed in other cases 
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of mouse and human meningitis resulting from infections 
with bacteria (E. coli, Cryptococcus neoformans, Myco-
bacterium tuberculosis), fungi and protozoa (Toxoplasma 
gondii) (supplementary Figs. 2, 3, online resource). All 
these data demonstrate HIF-1α activation in both inflam-
matory and resident CNS cells upon meningitis in mice 
and humans.
Activation of HIF‑1α in brain endothelial cells 
upon in vitro pneumococcal infection
It is known that the activation of the HIF-1α/VEGF pathway 
contributes to permeability of ECs [1, 25]. As HIF-1α acti-
vation was detectable in pneumococcal meningitis samples 
(Fig. 1), we hypothesized a critical role for this pathway in 
bacterial transfer across the BBB in infections. We infected 
brain ECs (immortalized brain endothelial cell line bEnd5) 
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with two different S. pneumoniae strains (D39, TIGR4) 
in vitro to mimic bacterial interference at the BBB formed 
in vivo by ECs and co-regulated by pericytes and astrocytes. 
To investigate the mechanisms of S. pneumoniae transfer 
across BBB, which is an early event followed by bacterial 
replication in the parenchyma [68], we infected the brain 
ECs for a short duration of 2–6 h. Prolonged infection time 
caused a non-specific breakdown of the endothelial mon-
olayer due to bacterial overgrowth and endothelial cell death. 
Induction of hypoxia known to trigger HIF-1α activation was 
analyzed by pimonidazole hydrochloride (Hydroxyprobe®, 
USA) staining and via direct quantification of oxygen con-
sumption. Cellular morphology indicated dramatic effects 
on monolayer integrity upon infections, particularly for 
TIGR4. Infection resulted in a strong accumulation of pimo-
nidazole indicating cellular hypoxia (Fig. 2a) and this was 
paralleled by a strong  O2 decrease in S. pneumoniae-infected 
cell medium to below 2% after 3 h due to bacterial con-
sumption (Fig. 2b). Congruently, hypoxic conditions were 
followed by HIF-1α activation as demonstrated by strongly 
elevated HIF-1α protein levels with both strains (~ three-fold 
induction, Fig. 2c) and via HIF-1α qRT-PCR (~ two-fold 
induction, Fig. 2d). Accordingly, VEGF, a confirmed target 
gene of the HIF-1α signaling cascade, was also induced in 
qRT-PCRs (~ three-fold induction, Fig. 2d). HIF-1α activa-
tion and VEGF induction were independent of the bacterial 
capsule (supplementary Fig. 4, online resource). Taken 
together, these results demonstrate a hypoxic HIF-1α/VEGF 
cascade in S. pneumoniae infections in vitro.
Transmigration of bacteria and endothelial 
permeability upon pneumococcal infection 
in an in vitro BBB model
As VEGF, a potent vascular permeability factor [1, 25], is 
induced by S. pneumoniae (Fig. 2), we assessed transmi-
gration and localization of S. pneumoniae (D39 strain), fol-
lowed by permeability analysis in an in vitro BBB model 
comprising brain ECs. For this, a transwell experimental 
setup was established with bEnd5 cells seeded on top of 
the insert (Fig. 3a). Infection was performed after 6 days 
when the cells formed confluent and tight monolayer mim-
icking a mature BBB in vitro. Infection from the apical 
side (top chamber) for 4 h led to the transmigration of ~ 1% 
bacteria across the EC monolayer into the bottom cham-
ber (Fig. 3b). To confirm that the cells were not affected 
by bacterial overgrowth, the monolayers were stained for 
S. pneumoniae and ECs 4 h post-infection as described [8]. 
The endothelial marker VE-cadherin staining was junctional 
in all cells and their morphology appeared spindle shaped 
as expected for BBB ECs with no indication of gross cell 
layer disruption due to the infection (Fig. 3c). S. pneumo-
niae adhered to ECs predominantly at the cell–cell borders, 
suggesting a paracellular mode of transmigration across 
the ECs. We therefore performed paracellular permeability 
assays using fluorescently labeled dextrans of two different 
sizes (3 kD and 70 kD) to obtain size-specific permeability 
of ECs. Results showed a significant increase in the perme-
ability of bEnd5 cells to both sizes of dextran upon infection 
with D39 or TIGR4 strains (Fig. 3d), which is supported 
by decrease in expression of junction molecules (supple-
mentary Fig. 5, online resource). Continuous impedance 
measurements of ECs in the CellZscope device revealed 
reduced transendothelial electrical resistance (TEER) com-
mencing 3 h post-infection that persisted up to 8 h (Fig. 3e, 
f). Increase in EC permeability was also present in infec-
tions with capsule-deficient mutants in line with induction 
of HIF-1α and VEGF by these strains (supplementary Fig. 4, 
online resource). Summarized, these data show that infection 
with S. pneumoniae results in bacterial translocation and a 
breakdown of barrier function in an in vitro BBB model
Neurovascular permeability and CNS 
deposition of S. pneumoniae in a murine model 
of hematogenous infection
As a hematogenous infection model is most appropriate for 
bacterial transmigration studies across BBB, we infected 
mice intraperitoneally with S. pneumoniae and assessed 
Fig. 1  Induction of HIF-1α in mouse and human brain tissue sam-
ples from pneumococcal meningitis. a Immunohistochemistry of 
brain tissue 36  h post-S. pneumoniae infection in intracerebrally 
infected mouse model shows positive HIF-1α in several inflammatory 
and neural cells. b Zoomed area from a in the cortex region of the 
infected mouse brain shows significant nuclear HIF-1α (black arrows) 
indicating its activation along with positive staining in the granulo-
cytic infiltrate. c Non-infected hemisphere of the same mouse at 36 h 
post infection shows no specific staining for HIF-1α signal. d Posi-
tive staining in the cortex region (black arrows) was also observed at 
24 h post-intracerebral infection, which was also observed at e 48 h 
post-infection in the intracisternally infected mice. f Control mice 
that were intracerebrally injected with 0.9% NaCl did not show any 
positive staining in the same region. g Brain sections from human 
pneumococcal meningitis patients double stained for HIF-1α (brown) 
and GFAP (red) show nuclear staining for HIF-1α (black arrows) in 
lymphocytes of the inflammatory infiltrate (g, left) and in the edem-
atous brain tissue comprising GFAP positive reactive astrocytes (g, 
right), where macrophages showed cytoplasmic staining (black cir-
cles). h Neurons labeled with MAP2 (red) were also co-stained with 
HIF-1α (brown) in the cortex but mostly the pyknotic ones and not 
the vital neurons (black circles). i Positive HIF-1α staining could also 
be observed in vessel associated cells in the cortex region. j Acti-
vated HIF-1α indicated by nuclear staining (red) could be observed 
in brains ECs from pneumococcal meningitis patients by immuno-
fluorescence staining using CD31 as an endothelial marker. Scale bar 
b–f is 20 µm, g–i is 25 µm, j left most image 20 µm and the zoomed 
images 10 µm. Mouse brain stainings are representative of three mice 
each at 24, 36, 48 h post-infection and two control mice at 48 h post- 
vehicle injection. Human pneumococcal meningitis stainings are rep-
resentative of 4 cases outlined in Table 1
◂
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the course of infection by plating of infected blood and 
subsequent CFU determination (Fig. 4a). In the infected 
mice, we detected a significant amount of bacteria depos-
ited in the brain compared to blood levels revealing a suc-
cessful transmigration process of S. pneumoniae over the 
BBB or the blood–CSF barrier (Fig. 4b). Peripheral infec-
tion was confirmed with even greater level of bacteria in 
the kidneys where the vascular barrier is leakier compared 
to the BBB. Permeability analysis of the injected 3 kD 
dextran tracer indicated a higher dextran levels in the brain 
of infected animals compared to healthy controls, whereas 
the kidney levels of the tracer were in the same range but 
higher compared to the brain levels, indicating a greater 
basal permeability of the kidney vasculature (Fig. 4c, d). 
Similar serum levels confirmed the presence of injected 
tracer in all the animals analyzed (Fig. 4e). The increase in 
BBB permeability in vivo upon infection could also result 
from dysfunction of other NVU cells (supplementary 
Fig. 6, online resource). The increase in EC permeability 
upon S. pneumoniae infection both in vitro and in vivo 
and the localization of S. pneumoniae in bEnd5 cells at the 
cell–cell junctions suggest a paracellular route of bacterial 
transmigration across the BBB.
Fig. 2  Hypoxia and HIF-1α/VEGF induction upon S. pneumo-
niae infection in brain ECs. a Control and S. pneumoniae infected 
bEnd5 cells treated with pimonidazole hydrochloride (Hypoxyprobe 
200 mM) and visualized for cellular hypoxia by red 549-linked mouse 
anti-pimonidazole monoclonal antibodies. D39 and TIGR4 strains 
infected cells show significantly high number of hypoxic cells com-
pared to control cells which is however not present in the top row 
without the probe indicating specificity of the staining (scale bar 
10 µm). b Oxygen levels (%) were quantified in the medium of con-
trol and S. pneumoniae infected bEnd5 cells using the SensorDish® 
Reader (SDR) for non-invasive measurement of  O2 levels through the 
transparent well bottom.  O2 concentration (pO2% air saturation) was 
obtained at 60-s intervals and average values at several different time 
points shown indicate a significant reduction in  O2 levels within min-
utes post-infection and to hypoxic levels by 2 h (N = 3, 2-tailed paired 
t test compared to control for each condition at the corresponding 
time point, mean ± SEM, **p < 0.01, ***p < 0.001), which was how-
ever not present either in control or deferoxamine (DFO, 200 µM), an 
iron chelator that induces HIF-1α independent of hypoxia. c Control 
and S. pneumoniae infected bEnd5 cells were analyzed for HIF-1α 
protein induction by Western blotting. The result shows a significant 
increase in HIF-1α levels in both D39 and TIGR4 infected cells com-
pared to control conditions when the band pixel intensity is quantified 
by normalizing to the housekeeping protein β-actin band. DFO served 
as a positive control for HIF-1α induction (N = 4, *p < 0.05, 2-tailed 
paired t test compared to control for each condition). d Quantita-
tive RT-PCR expression analysis (by  2−∆∆Ct method) of control and 
infected bEnd5 cells shows upregulation of HIF-1α and its transcrip-
tional target gene VEGF upon a S. pneumoniae infection. Expression 
was normalized to ribosomal protein, large, P0 (RPLP0) that served 
as a housekeeping gene (N = 6, *p < 0.05, **p < 0.01, 2-tailed paired t 
test compared to control)
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Fig. 3  Bacterial transmigration and permeability upon S. pneumoniae 
infection in brain ECs. a The scheme depicts the in  vitro model of 
the BBB for meningitis infection where bEnd5 cells were cultured 
in 24-well PET transwells  (105 cells/cm2) and infected with S. pneu-
moniae (D39 and TIGR4 strain; MOI 50) along with the addition of 
labeled dextrans to the apical chamber (5 μM each of 3 kD TMR, and 
70 kD FITC dextran). b Media supernatant from infected and con-
trol cells from the insert and the bottom well at 4  h post-infection 
were collected and centrifuged for plating and culture on blood agar 
plate. The colony forming unit (CFU) assay indicates transmigra-
tion of approximately 1% of the bacteria added to the insert (N = 5, 
***p < 0.001, 2-tailed paired t test compared to control). c Confocal 
microscopy analysis of transwell inserts to confirm the presence of 
bacteria indicated predominant localization of the bacteria (green) at 
the cell–cell borders with VE-cadherin (red) serving as EC junction 
marker (representative from N = 3 experiments; scale bar 10 μm). d 
Permeability analysis of bEnd5 cells 4  h post-infection performed 
with low (3 kD) and high molecular weight (70 kD) dextrans shows 
a significant increase in dextran permeability for both sizes, con-
firming the breakdown of endothelial barrier due to infection (N = 5, 
*p < 0.05, **p < 0.01, 2-tailed paired t-test compared to control). e 
Representative graph for continuous transendothelial electrical resist-
ance (TEER) values of S. pneumoniae (D39) infected bEnd5 cells on 
inserts using the cellZscope® system setting the values of the con-
trol group between 3–4  h post-infection to 100%. The graph shows 
reduced TEER values starting 3  h post-infection that persists for 
several hours indicating increase in paracellular permeability. The 
increase in the TEER values of the control group from the plateau at 
0 h reflects the changes due to electrode handling and media compo-
sition. f Quantification at 4 h shows a significant reduction in TEER 
values in infected cells compared to control (N = 4, *p < 0.05, 2-tailed 
paired t test)
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Paracellular localization and transmigration of S. 
pneumoniae across brain ECs
To confirm the localization of S. pneumoniae observed 
in bEnd5 cells (Fig. 3c), we performed confocal analy-
sis of infected primary brain ECs isolated from wild-type 
mice and quantified the number of bacteria close to cell 
junctions. S. pneumoniae adhered to primary ECs also 
at the cell–cell borders and their quantification indicated 
a predominant localization close to the cell–cell junc-
tions (Fig. 5a, b). To confirm these observations in vivo, 
electron microscopy was performed on hematogenously 
infected mice. Meningeal infection was confirmed by 
the presence of extravascular bacteria in the meninges 
(Fig. 5c, bacteria colored green). Both in meninges and 
cortex regions (Fig. 5d–i), S. pneumoniae localization was 
at the cell–cell junctions, which was verified in several 
infected mice (supplementary Fig. 7, online resource). To 
test whether this localization also appears in human BBB, 
primary human brain ECs were infected with S. pneu-
moniae and subjected to super-resolution microscopy 
(SRM). Bacterial localization was again predominantly 
at the cell–cell junctions (Fig. 5j, k). To unequivocally 
demonstrate the paracellular preference of S. pneumoniae 
in transmigration across brain ECs, we performed live-
cell imaging analysis of primary mouse brain ECs infected 
with these bacteria. At 2 days post-isolation, MBMEC 
were infected (MOI 10) with GFP-labeled D39 S. pneu-
moniae strain [40], followed by live-cell imaging. Within 
2 h post-infection, several bacteria transmigrated across 
cell–cell borders with a duration of 30–45 s to transmi-
grate once localized in the paracellular space, as observed 
in the time lapse images and video (Fig. 5l and supplemen-
tary video 1, online resource). Taken together, these data 
demonstrate a paracellular route for transmigration of S. 
pneumoniae across brain ECs at the BBB.
Fig. 4  Extravasation of S. pneumoniae and neurovascular perme-
ability in vivo in a hematogenous meningitis model. a Setup showing 
the murine infection model with intraperitoneal injection of 0.5 × 105 
bacteria (in 100 μl PBS, D39 strain). 18 h post-infection mice were 
injected with a 3kD TMR tracer (i.p), circulated for 20 min followed 
by anesthesia, transcardial PBS perfusion and collection of blood, 
brain, and kidney. b Homogenized organs or blood were plated and 
cultured overnight to obtain the bacterial counts using the CFU assay. 
High CFU values in blood indicated the hematogenous presence of 
bacteria with extravasation of bacteria evident in the brain (0.01%). 
The bacterial counts in the kidney were 100-fold higher than brain 
reflecting higher permeability of the kidney vasculature. Healthy con-
trol mice did not have any bacterial growth on the plates. c Homog-
enized hemi-brain, kidney and blood were utilized to obtain dextran 
permeability by measuring fluorescence intensity on a microplate 
reader. A significant elevation in vascular permeability of infected 
mice was observed compared to healthy controls in the brain indi-
cating blood–brain barrier breakdown. d Vascular permeability of 
kidney was not altered upon infection. e Serum fluorescence values 
(arbitrary units—a.u.) indicate equivalent tracer absorption between 
healthy and infected mice. (N = 5–7/group, *p < 0.05, 2-tailed 
unpaired t test)
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Regulation of HIF‑1α/VEGF signaling at the BBB 
in murine pneumococcal meningitis
The BBB is the critical interface in the initiation of men-
ingitis. We therefore analyzed gene regulation and signal-
ing pathways in the BBB forming microvessels. Mice were 
intraperitoneally infected and brain microvessels were iso-
lated for RNA sequencing and bioinformatic analyses as 
described previously [37, 16] comparing them with healthy 
controls (Fig. 6a). The dataset has been uploaded to NCBI 
GEO database (ID: GSE122952). As observed via principal 
component analysis (PCA) and the corresponding volcano 
plots, gene expression at the BBB in meningitis is signifi-
cantly altered with ~ 20% (4,382 genes) genes upregulated 
and ~ 20% (4,354) downregulated; the complete hierarchical 
clustering data are included (supplementary Fig. 8, online 
resource). The top 25 regulated genes (based on significance) 
are shown in the heatmaps (Fig. 6b, c). Also, in this in vivo 
murine pneumococcal meningitis model, we observed an 
upregulation of HIF-1α and VEGF at the BBB (Fig. 6d). 
Several genes known to be regulated by HIF-1α, such as 
angiopoietin2, Tie2, PTPRB that we reported previously 
for their role in BBB function in ischemic stroke and brain 
tumors [27, 37, 16], were dysregulated in the infected mice. 
Additionally, several BBB junctional genes such as occlu-
din, claudin-5, and ZO-1 were found to be downregulated 
indicating a BBB breakdown (Fig. 6d). Several proinflam-
matory cytokines such as IL1β and TNFα were also induced, 
indicating the inflammatory status of the mice at the BBB 
level. Bioinformatic analyses using KOBAS indicated the 
activation of HIF-1α/VEGF pathway independently by path-
way enrichment analysis in PANTHER and KEGG databases 
(see green arrows, Fig. 6e, f) and also in Reactome database 
analysis (supplementary Fig. 9, online resource). Several 
related pathways such as NF-kappa B, PI3K-Akt, Jak-STAT, 
Ras and PDGF were also activated at the BBB upon pneu-
mococcal infection. Pathways related to vascular remodeling 
and angiogenesis were also activated indicating a gross BBB 
dysfunction in meningitis (red arrows in Fig. 6e, f). These 
data strongly support the involvement of HIF-1α/VEGF 
pathway at the BBB in vivo in pneumococcal meningitis.
HIF‑1α dependence of BBB permeability in S. 
pneumoniae infections
We demonstrated that S. pneumoniae infection in vitro 
and in vivo induced expression of HIF-1α and its target 
gene, VEGF in the brain endothelial cells and also leads to 
increased permeability (see above). However, as VEGF is 
known to induce paracellular permeability in brain ECs [1] 
and given the paracellular localization of S. pneumoniae in 
these cells, we investigated whether the permeability upon 
bacterial infection is mediated by HIF-1α/VEGF pathway. 
To this end, we first utilized echinomycin, a potent chemi-
cal inhibitor of HIF-1α [43]. In bEnd5 cells, echinomycin 
treatment followed by S. pneumoniae infection prevented 
EC permeability to low or high molecular weight dextrans 
when compared to untreated controls (Fig. 7a). Furthermore, 
echinomycin treatment reduced bacterial transmigration 
into the bottom chamber across the endothelial monolayer 
(Fig. 7b). Similar effects on permeability were also observed 
in bEnd5 cells upon siRNA-mediated knockdown of HIF-1α 
(Fig. 7c), the efficiency of which was verified by qRT-PCR 
(not shown). To confirm these results, we performed infec-
tions in primary brain ECs. However, as primary brain 
ECs are not amenable to transfection, we utilized a mouse 
model that is homozygous for a floxed allele of HIF-1α at 
the corresponding locus (HIF-1αflox/flox, [62]). Brain ECs 
were isolated from HIF-1αflox/flox mice as shown in the 
schematic (Fig. 7d), followed by treatment with TAT-Cre, a 
cell-permeable cre-recombinase for in vitro recombination 
of loxP sites to knock out HIF-1α in isolated cells. Treatment 
of brain ECs resulted in a ~ 50% knockdown of HIF-1α as 
shown by qRT-PCR (Fig. 7e). HIF-1α knockdown in these 
primary brain ECs resulted in a reduction of permeability (3 
kD and 70 kD dextrans) back to the level of uninfected cells 
(Fig. 7f). Similar results were also obtained in human brain 
ECs by siRNA-mediated knockdown of HIF-1α (supplemen-
tary Fig. 10, online resource). These data demonstrate that S. 
pneumoniae-induced permeability is dependent on HIF-1α/
VEGF pathway.
Therapeutic rescue of murine S. pneumoniae 
infection by echinomycin to inhibit HIF‑1α
Echinomycin, a potent small molecule inhibitor of HIF-1α, 
was used as anti-HIF-1α treatment to therapeutically res-
cue mice infected with S. pneumoniae. Adult wild-type 
mice were intraperitoneally infected with S. pneumoniae as 
described previously, followed by treatment with echino-
mycin every 12 h starting 4 h post-infection. This survival 
study was conducted for 48 h with clinical scoring every 
4 h starting 16 h post-infection. The experimental design 
is shown in Fig.  8a. Compared to the vehicle-treated 
mice, the echinomycin-treated mice showed significantly 
improved clinical scores at several time points starting 
16  h post-infection which was maintained up to 28  h 
(Fig. 8b). Both, the overall survival and progression-free 
survival, as anticipated from improved clinical scores, 
were significantly improved in the treated animals suggest-
ing a therapeutic rescue of pneumococcal infection with 
echinomycin (Fig. 8c, d). Immunohistochemistry (IHC) 
at the end point revealed significant reduction in HIF-1α-
positive cells including brain ECs (co-stained for podoca-
lyxin, a vessel marker) in the group treated with echinomy-
cin, indicating it is specific in HIF-1α inhibition (left panel 
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in both Fig. 8e, f). Analysis of BBB function indicated 
reduced extravasation of fibrinogen from the brain vessels 
of echinomycin-treated animals compared to the vehicle 
group (middle panel in Fig. 8e, f). This was supported by 
the increased expression of tight junction markers occludin 
and claudin-5 in the echinomycin group compared to the 
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vehicle group (Fig. 8e middle and right-top panels and 
quantified in Fig. 8f right panel). However, EC adhesion 
molecule CD-31, vascular glycocalyx member podoca-
lyxin, adherens junction member VE-cadherin, and tight 
junction-associated molecule ZO-1 were all unchanged 
between the two groups (Fig. 8e, f). Interestingly, S. pneu-
moniae staining in the vessels (v-Spn) and in brain paren-
chyma (b-Spn) was unchanged between the groups (Fig. 8e 
right top, quantified in Fig. 8f middle panel), suggesting 
an absence of bactericidal effects of echinomycin in this 
murine model. Comparison to control healthy animals by 
immunohistochemistry confirmed the improved BBB func-
tion by echinomycin compared to the vehicle (supplemen-
tary Fig. 11, online resource). Overall, these data demon-
strate improvement of BBB function by HIF-1α inhibition 
with echinomycin, leading to improved clinical symptoms 
and survival post-pneumococcal infections.
Discussion
The homeostasis of the CNS is maintained by the BBB, 
which is formed by brain ECs and co-regulated by other 
cells of the NVU. The tight junctions between the ECs and 
the efflux transporters expressed on their plasma mem-
branes limit the transport of blood-borne solutes and path-
ogens [46]. In bacterial meningitis, the circulating bacteria 
first enter the CNS via the BBB or the blood–CSF barrier 
(BCSFB), consequently leading to infection and the ensu-
ing neurological complications, mainly cerebral edema 
and elevated intracranial pressure. The most frequent 
pathogen causing bacterial meningitis is S. pneumoniae 
that commonly resides in the mucosal layers of the naso-
pharynx, but occasionally penetrates the tissue barriers, 
leading to invasion and survival in the blood stream. Men-
ingitis results when the blood-borne pathogens translocate 
across the BBB and cause CNS infection [18]. Bacterial 
transmigration across the BBB is therefore a critical step 
in the course of disease.
Involvement of endothelial β2-adrenoreceptor has been 
identified in transmigration of meningococcal pathogens 
across the BBB [7]. Bacterial induction of Snail in brain 
ECs has been reported in group B streptococci (GBS) 
meningitis, leading to disruption of the BBB and penetra-
tion of meningeal pathogens [39]. Interaction of S. pneu-
moniae with platelet activating factor receptor (PAFR) 
[33, 60] and also with polymeric Ig receptor and PECAM 
was demonstrated to be important for bacterial adhesion 
including for brain endothelium [34]. However, the exact 
mechanisms in the host endothelium responsible for bac-
terial transmigration and their route of transmigration are 
still poorly understood in pneumococcal meningitis [18, 
33, 38].
We have previously reported that HIF-1α activation and 
the induction of its target gene VEGF [28, 75] is a general 
phenomenon in a broad variety of infections due to bacte-
ria, fungi and viruses and characterized this phenomenon 
in more detail in Bartonella henselae infections, leading 
to vasculoproliferative disorders [35, 36, 59]. Increased 
VEGF levels were also reported in inflammatory infiltrates 
of bacterial meningitis autopsy specimen [72]. Further-
more, oxidative stress due to excessive production of reac-
tive oxygen species (ROS) has been reported in several 
studies during pneumococcal meningitis, again suggest-
ing a potential involvement of HIF-1α, as ROS is a well-
known HIF-1α activator [14, 41]. Given the established 
role of HIF-1α/VEGF signaling in endothelial permeabil-
ity [1, 23, 25], we hypothesized a critical role for this path-
way in the BBB permeability and bacterial transmigration 
in meningitis. Immunohistochemistry of murine pneumo-
coccal meningitis samples revealed activated HIF-1α in 
Fig. 5  Junctional localization of S. pneumoniae at the BBB in  vitro 
and in  vivo. a Primary mouse brain ECs (MBMEC) were infected 
with S. pneumoniae and subjected to immunofluorescence staining 
for claudin-5 to mark endothelial junctions (red) and co-stained with 
an anti-pneumococcal antibody (green) to label S. pneumoniae. Con-
focal fluorescence microscopy of EC monolayers indicated a predom-
inant localization of bacteria at the cell–cell borders co-localizing 
with claudin-5, an endothelial tight junctions marker as shown by b 
quantification that indicated a significantly higher number of bacte-
ria close to the junctions. N = 3 independent preparations of MBMEC 
from 2–3 mice each time. Two independent wells were counted for 
each set comprising approximately 25 cells/field at 60X magnifica-
tion (scale bar: 20  μm). Bacteria within a distance of 1 bacterium 
equivalent size from the junction were considered close to the junc-
tion. Data presented as mean ± SEM, **p < 0.01, 2-tailed paired t test. 
c–i Transmission electron microscopy (TEM) analysis was performed 
on brain sections from hematogenously infected mice post-perfusion 
with PBS/PFA and fixation in PFA/glutaraldehyde. S. pneumoniae 
either directly or in protective membrane bound vesicles were local-
ized at the endothelial tight junctions both in meninges and cortex in 
several mice analyzed (representative images from N = 6 mice sub-
jected to TEM). Artificial coloration was performed for better visu-
alization and to highlight the localization of S. pneumoniae. SPN-S. 
pneumoniae, EC-endothelial cell, PC-pericyte, LU-lumen, BL-basal 
lamina, AEF-astrocytic endfeet, ERY-erythrocyte. j–k Primary 
human brain ECs (HBMEC) were also infected with S. pneumoniae 
and stained with anti-pneumococcal antibody and claudin-5 and sub-
jected to super resolution microscopy using Nikon structured illumi-
nation microscopy (N-SIM). In 2 different preparations of HBMEC, 
the localization of bacteria was primarily at the junctions with super 
resolution images demonstrating engagement of S. pneumoniae with 
the endothelial junctions (Figures to the right both in j, k). Scale 
bar: 5 μm. l Primary mouse brain ECs (MBMEC) were infected with 
GFP-labeled S. pneumoniae strain (MOI 10) 2 days post-isolation and 
subjected to live-cell imaging. MBMECs as well as bacteria were 
imaged in brightfield and GFP fluorescence channel every 10 s start-
ing 1 h post-infection for a total of 2 h. Five time-lapse images (10-s 
interval) capture transmigration of few bacteria across cell–cell bor-
ders (whites lines), which demonstrate paracellular route for transmi-
gration of S. pneumoniae across brain endothelial cells. Representa-
tive images from 1 preparation from N = 3 MBMECs preparations (1 
animal/set) infected with GFP-labeled D39 strain. Scale bar: 10 μm.
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the brain and this finding was confirmed in human pneu-
mococcal and other bacterial meningitis autopsy speci-
men. In brain ECs (bEnd5 cells), pneumococcal infection 
with clinical S. pneumoniae isolates (D39, TIGR4) led 
to dramatic reduction of oxygen levels within minutes 
of infection, leading to hypoxia that persisted for hours 
resulting in HIF-1α activation at RNA and protein levels in 
brain ECs. Furthermore, the infections led to an induction 
of VEGF, a known target gene of HIF-1α transcriptional 
activity. As VEGF causes paracellular permeability in ECs 
[1, 25], we utilized a transwell setup with apical infection 
of bEnd5 monolayers to assess permeability. Deposition 
of bacteria in the basal chamber and their predominant 
localization at the cell–cell borders suggest a paracellular 
transmigration of bacteria. Permeability analysis using dif-
ferent sizes of dextran showed an increase, which is reflec-
tive of paracellular permeability as brain ECs undergoes 
minimal fluid-phase transcytosis. These data are also sup-
ported by reduced TEER values upon infection obtained 
from continuous impedance measurements [8]. To elabo-
rate the mechanisms of bacterial transmigration across 
the brain endothelium in vivo, an intraperitoneal infec-
tion model was used where pneumococci are distributed 
hematogenously with deposition in the CNS. When ana-
lyzing permeability and bacterial localization (via electron 
microscopy, super-resolution microscopy and confocal 
microscopy), we observed increased vascular permeabil-
ity and localization of bacteria at the cell–cell junctions 
in brain ECs. Paracellular transfer of S. pneumoniae was 
also observed by live-cell imaging of primary brain ECs 
infected with of GFP-labeled bacteria. From this data, we 
conclude that S. pneumoniae utilize paracellular pathway 
for transmigration across the BBB in meningitis.
As our data argue for an involvement of HIF-1α/VEGF 
from both in vitro infection experiments and from immu-
nohistochemical analysis of meningitis samples, we elab-
orated HIF-1α/VEGF expression in vivo at the BBB. To 
this end, brain microvessels were freshly isolated post-
infection and RNA sequencing was performed to obtain 
the transcriptional changes in an unbiased manner as we 
described previously [37, 16]. Hematogenous infection of 
S. pneumoniae resulted in global transcriptional changes 
in the BBB microvessels demonstrated by the regulation 
of ~ 9000 genes out of ~ 21,000 genes. Several BBB junction 
molecules were found to be downregulated in meningitis 
including occludin, claudin-5 and ZO-1, highlighting the 
BBB breakdown. Several proinflammatory cytokines were 
found to be upregulated such as IL-1β and TNF-α, support-
ing increased inflammation as observed in bacterial menin-
gitis cases [57, 68]. Further analysis indicated a significant 
upregulation of HIF-1α and VEGF and these findings were 
supported by bioinformatics pathway analyses, showing 
increased HIF-1α/VEGF signaling at the BBB in meningitis. 
Junctional localization of bacteria and increased paracellular 
permeability upon infection establish a paracellular path-
way for bacterial transmigration at the BBB. This is fur-
ther supported by downregulation of junctional molecules, 
unchanged transcellular permeability factor plasmalemma 
vesicle associated protein (PLVAP), and potentially com-
pensatory decrease in caveolin-1 (based on RNAseq data). 
Given that VEGF is a known permeability factor targeting 
junctions in the paracellular pathway [1, 25], we next tested 
if infection-induced HIF-1α/VEGF is required for bacterial 
transmigration and permeability at the BBB. Inhibition and 
knock-down of HIF-1α resulted in rescue of permeability 
and bacterial transmigration post-infection, thus demonstrat-
ing a critical role for HIF-1α/VEGF in bacterial transmigra-
tion and permeability at the BBB in meningitis.
RNAseq analysis also indicated regulation of several 
pathways related to HIF-1α and VEGF such as NF-kap-
paB, PDGFb and Ang/Tie2 signaling, as reported pre-
viously for RNAseq of brain microvessels from experi-
mental stroke and glioma models [37, 16]. In the current 
meningitis data set, we observe an increase in angiopoi-
etin 2 (Ang-2) and a decrease in Tie2 as well as protein 
tyrosine phosphatase receptor type B (PTPRB; one of 
the top down-regulated genes). We previously described 
that increased levels of Ang-2 contribute to BBB break-
down in healthy and ischemic mice which was rescued by 
Fig. 6  Regulation of HIF-1α/VEGF signaling by RNAseq analysis of 
brain microvessels from S. pneumoniae infected mice. a Schematic of 
BBB microvessels isolation for RNAseq analysis showing intraperito-
neal injection of bacteria followed by anesthesia and transcardial per-
fusion 18 h post-infection. Extracted brains were cleared of meninges, 
olfactory lobes, and cerebellum and homogenized followed by myelin 
removal (density centrifugation). The microvessels were separated by 
filtering through 100  μm nylon mesh and collected from the top of 
40 μm mesh. b The PCA plot shows clear clustering of healthy and 
meningitis microvessels with the volcano plot showing close to 9000 
differentially expressed genes (DEG). c Heatmap analysis shows top 
25 upregulated and downregulated genes by Z-score transformation. 
The data are displayed in a grid where each row represents a gene 
and each column represents the sample replicate. d Visualization 
of actual base reads of gene expression by RNAseq profiling shows 
upregulation of HIF-1α, VEGF and inflammation-related genes such 
as IL1b and ANGPT2. BBB junction molecules claudin-5, occludin, 
ZO-1 were downregulated, indicating breakdown of the BBB in this 
mouse model at the transcriptomic level. e PANTHER pathway anal-
ysis of the RNAseq data illustrates the activation of pathways related 
to angiogenesis (red arrow) and HIF-1α/VEGF signaling, and the 
ones related to them such as PDGF, p53 pathways (green arrows). f 
The KEGG pathway enrichment also indicated activation of HIF-1α/
VEGF signaling, and related pathways driven by NF-kappa B, PI3-
Akt, Jak-STAT, and Ras signaling (green arrows). Pathways related 
to cancer and vascular remodeling were also activated (red arrows) 
including those related to inflammation. Dotted line in e, f indicates 
the cutoff value for significance with color coding for significance 
level (lighter being more significant) and bubble size reflecting the 
number of genes in the significant hits (N = 4 samples/group pooling 
2 brains per sample)
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activating Tie2 signaling via targeting PTPRB (also known 
as vascular endothelial protein tyrosine phosphatase VE-
PTP) [27]. Interestingly, VE-PTP has been shown to be 
regulated by hypoxia in vitro in HUVECs and in vivo in 
a mouse model of oxygen-induced retinopathy [65], sug-
gesting a similar regulation in meningitis as indicated 
by our sequencing data. Ang-1, the endogenous Ang-2 
antagonist, has been reported to prevent VEGF-induced 
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permeability by sequestering the tyrosine protein kinase 
Src via mDia. This leads to inhibition of VEGF down-
stream signaling via VEGF receptor 2 (VEGFR2) that 
requires activation of Src [26], whereas Ang-2 has been 
shown to be synergistic with VEGF in tumor angiogenesis 
and permeability including in brain tumors that are char-
acterized by significant BBB damage [64]. A paracellular 
pathway involving β2-adrenoreceptor/β-arrestin via Src 
kinase leading to disorganization of junctional molecules 
has been reported for transmigration of Neisseria menin-
gitidis across the BBB causing meningococcal meningitis 
[7]. Interestingly, β-arrestin-dependent endocytosis of VE-
cadherin promoted by VEGF leads to paracellular perme-
ability [25], which suggests that the upstream signaling in 
N. meningitidis transmigration might also involve HIF-1α/
VEGF pathway in addition to β2-adrenoreceptor signal-
ing. SNAI1 (Snail) has also been shown to contribute to 
BBB permeability in meningitis caused by GBS and poten-
tially to bacterial transmigration [39] and this observa-
tion is supported by our RNAseq dataset showing twofold 
upregulation of Snail. Interestingly, Snail transcriptional 
activity via repression of VEGFR2 has been recently dem-
onstrated in cancer resistance with beneficial outcome in 
tumor growth upon co-targeting of these pathways [47]. 
Potential interference of these pathways at the BBB in 
meningitis cannot be therefore ruled out.
Based on the in vitro data and RNAseq analysis that indi-
cated a crucial role of HIF-1α pathway at the BBB in menin-
gitis, we targeted the HIF-1α pathway for therapeutic rescue 
in a murine model of pneumococcal infection. Mice hematog-
enously infected with S. pneumoniae survived longer and with 
better clinical symptoms upon treatment with echinomycin, a 
potent HIF-1α inhibitor. While HIF-1α was indeed reduced in 
the treated animals, no difference was observed in the levels 
of S. pneumoniae either in the vessels or in the brain paren-
chyma. Analysis of blood–brain barrier function indicated 
reduced fibrinogen permeability and increased expression of 
tight junction proteins occludin and claudin-5, suggesting BBB 
improvement with echinomycin treatment. These results sug-
gest that the primary mechanism of improved survival/clinal 
symptoms upon echinomycin treatment might be the result of 
improved BBB function upon inhibition of HIF-1α signaling. 
A bactericidal effect of echinomycin, however, can be ruled 
out as we observed similar levels of vascular bacteria in both 
echinomycin- and vehicle-treated groups. This is in line with 
a previous report employing echinomycin as a peptide antibi-
otic in a murine model of intraperitoneal S. aureus infection 
where the effective dose was 50–100 times of that applied in 
the current study [55]. Our in vitro bacterial growth data upon 
echinomycin treatment also support these results (not shown). 
At the low doses applied in the current study, inhibition of 
HIF-1α has however been shown to be effective in murine can-
cer models where echinomycin treatment resulted in increased 
survival [67, 73]. Similar to the in vitro findings, BBB tighten-
ing with echinomycin could lead to reduced bacterial numbers 
in the brain parenchyma at a particular time point post-infec-
tion compared to the untreated animals. The unchanged brain 
parenchymal bacterial load in our study can be explained by 
our analysis, which was at the survival end point as opposed to 
same time point for all animals. However, even with a minimal 
effect of echinomycin on early BBB tightening and bacterial 
transmigration and CNS deposition, the long-term effect of 
improved BBB function could potentially lead to reduced brain 
edema and alleviate the neurological damage.
As the neurological complications of seizures, stroke, long-
term neurological disability and mortality are a result of initial 
BBB impairment and subsequent brain edema, therapeutic 
targeting of barrier function is a critical step in meningitis. 
Current strategies for bacterial meningitis utilize corticoster-
oids (mainly dexamethasone) as an adjuvant therapy in com-
bination with antibiotics [3, 41]. In several cases, dexametha-
sone is administered alone even before antibiotics to control 
the BBB dysfunction that leads to increased cerebral edema 
and intracranial pressure. However, the benefit of dexameth-
asone in patient survival or neurological improvement was 
not evident in several clinical studies for various pathogens 
causing bacterial meningitis [4, 71, 22, 10, 53, 63]. In one 
Fig. 7  HIF-1α-dependent endothelial permeability and transmi-
gration of S.  pneumoniae post-infection. a Treatment of brain ECs 
(bEnd5) with echinomycin (Ech), an HIF-1α inhibitor, did not lead 
to higher permeability post-S. pneumoniae infection (D39 strain) for 
both low (3 kD) and high molecular weight (70kD) dextrans, whereas 
untreated cells showed increase for both the tracers. Ech alone 
did not affect permeability when compared to uninfected controls. 
(mean ± SEM, N = 3, *p < 0.05, 2-tailed paired t test. b Ech treatment 
also led to significant reduction in the transmigrated bacteria across 
bEnd5 monolayers, which combined with Fig.  1a indicates HIF-1α 
dependence of both permeability and paracellular bacterial trans-
migration (mean ± SEM, N = 3, **p < 0.01, 2-tailed unpaired t test). 
c Genetic ablation of HIF-1α using siRNA-mediated knockdown in 
bEnd5 cells also demonstrated a decrease in permeability post-infec-
tion compared to scrambled controls (mean ± SEM, N = 4, *p < 0.05, 
2-tailed paired t test). d Schematic of primary mouse brain endothe-
lial cells (MBMEC) isolation and culture for permeability analysis 
post infection. Cerebral hemispheres from HIF-1αflox/flox mice cleared 
of meninges were homogenized followed by myelin removal and col-
lagenase digestion. Plated microvessels were treated with puromy-
cin to obtain pure EC cultures, followed by treatment with TATcre 
to induce knockdown of HIF-1α and seeded on to transwell inserts 
for infection and permeability analysis. e Quantitative RT-PCR con-
firmed about 50% knockdown of HIF-1α in MBMEC when normal-
ized to RPLP0 (a housekeeping gene), VE-cadherin (CDH5) was 
not changed (mean ± SEM, N = 5 MBMEC preparations pooling 2–3 
mice/set, **p < 0.01, 2-tailed paired t test). f Permeability analysis of 
MBMEC to both low and high molecular weight dextrans showed an 
increase post infection with S. pneumoniae (D39) as observed with 
bEnd5 cells. This effect was abrogated upon HIF-1α knockdown in 
TAT-cre treated cells demonstrating HIF-1α dependence of permea-
bility post infection also in primary brain endothelium (mean ± SEM, 
N = 6 MBMEC preparations pooling 2–3 mice/set, *p < 0.05, 
**p < 0.01, 2-tailed paired t test)
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study, dexamethasone therapy in HIV-associated Cryptococ-
cus neoformans meningitis was associated with even more 
adverse events including disability than the control group [4]. 
New effective therapeutic strategies are therefore needed to 
target the BBB dysfunction associated with meningitis [3]. 
The benefit of dexamethasone has also been questionable in 
cancer therapy as elaborated in our recent review [20], where 
it is used in edema management particularly in brain tumors 
[19, 30, 66]. Interestingly, one mechanism proposed for the 
action of dexamethasone on edema reduction in glioma was 
via downregulation of VEGF leading to reduced permeability; 
the efficacy of dexamethasone, however, was dramatically 
reduced during hypoxia [50]. The insignificant effects of dexa-
methasone in meningitis can thus be explained by the above 
study combined with ours, demonstrating the role of hypoxia 
and HIF-1α/VEGF in meningitis. Regulation of angiogen-
esis and cancer-related pathways at the BBB in meningitis as 
indicated by bioinformatics analysis of our RNA sequencing 
data further support the role of HIF-1α/VEGF in meningitis 
similar to their role in cancer progression [14, 11, 16]. Several 
cancer therapeutics target HIF-1α/VEGF pathway alone or in 
combination with other pathways to alleviate tumor angiogen-
esis and permeability [21, 64, 16]. Given the limited effects 
of dexamethasone in meningitis and based on our study that 
demonstrates a critical role of HIF-1α/VEGF in meningitis at 
the BBB, we propose that targeting this pathway in meningitis 
as demonstrated using echinomycin in this study could lead to 
effective therapeutics for this deadly disease.
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Fig. 8  Improved survival and blood–brain barrier function post pneu-
mococcal infection in mice by anti-HIF-1α treatment using echino-
mycin. a Schematic depicting treatment protocol of mice infected 
with S. pneumoniae (D39). Mice were infected i.p., followed by anti-
HIF-1α treatment with echinomycin or just vehicle every 12 h start-
ing 4  h post-infection (blue tick marks). Clinical scores were taken 
every 4 h starting 16 h post-infection (red line with tick marks) and 
study terminated at 48  h post-infection and brain tissues collected 
upon animal death or at the end point when the animals were sac-
rificed. b Clinical scores indicate improved symptoms in echinomy-
cin-treated mice compared to vehicle-treated animals starting 16  h 
post-infection that were progression free (below score 1) up to 24 h 
(mean ± SEM at each time, N = 10/group, ****p < 0.0001, **p < 0.01, 
*p < 0.05 by 2-tailed unpaired non-parametric Mann–Whitney t test 
at each time point. c Echinomycin-treated mice showed significantly 
improved overall survival percentage by Kaplan–Meier analysis with 
the median survival at 32 h compared to 25 h in vehicle-treated mice 
(**p < 0.01, log-rank test, N = 10/group). d Kaplan–Meier analysis 
also indicated a significant improvement in progression-free survival 
in echinomycin-treated animals (median survival 25 h) with no clini-
cal symptoms up to 24 h (b) compared to the vehicle group (median 
survival 17 h; ***p < 0.001, log-rank test, N = 10/group). e Immuno-
fluorescence staining for HIF-1α, BBB permeability and junctional 
markers in the echinomycin and vehicle groups at the survival end 
point. Left panel shows that echinomycin treatment leads to a reduc-
tion in HIF-1α-positive nuclei including in ECs co-stained for podo-
calyxin, a vascular marker which was unchanged by the treatment. 
Middle panel displays reduced vascular permeability to fibrinogen in 
the echinomycin group as indicated by stronger intravascular signal 
compared to the vehicle-treated mice. Increased expression of tight 
junction proteins—occludin (middle panel) and claudin-5 (right top 
panel)—in echinomycin-treated mice indicate improved BBB func-
tion. Tight junction-associated ZO-1, adherens junction marker 
VE-Cadherin, and endothelial cell adhesion molecule CD31 were 
unchanged (middle, bottom right panel). There was also no differ-
ence in S. pneumoniae (Spn) staining (right top panel) between the 
two groups. Scale bar 10 μm. f Quantification of the staining from e 
utilizing four images per animal in the cortex region shows a signifi-
cant reduction in HIF-1α-positive cell number, whereas the total cell 
number or EC cell number was unchanged (left panel). As observed 
in e, the middle panel for quantification (arbitrary units—a.u.) of 
fibrinogen leakage shows significantly increased vascular staining for 
fibrinogen, supported by significantly increased expression of occlu-
din, claudin-5, whereas other EC junction markers were unchanged. 
S. pneumoniae numbers in the vessels (v-Spn) or those transmigrated 
into brain parenchyma (b-Spn) were also unchanged. (mean ± SEM, 
N = 7–10/group indicated by the corresponding number of dots, 
****p < 0.0001, **p < 0.01, *p < 0.05 by 2-tailed unpaired Student’s 
t test)
◂
206 Acta Neuropathologica (2020) 140:183–208
1 3
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW 
(1999) Vascular endothelial growth factor induces rapid phospho-
rylation of tight junction proteins occludin and zonula occluden 
1. A potential mechanism for vascular permeability in diabetic 
retinopathy and tumors. J Biol Chem 274:23463–23467. https ://
doi.org/10.1074/jbc.274.33.23463 
 2. Balconi G, Spagnuolo R, Dejana E (2000) Development of endothe-
lial cell lines from embryonic stem cells: a tool for studying geneti-
cally manipulated endothelial cells in vitro. Arterioscler Thromb 
Vasc Biol 20:1443–1451. https ://doi.org/10.1161/01.atv.20.6.1443
 3. Barichello T, Collodel A, Generoso JS, Simoes LR, Moreira AP, 
Ceretta RA et al (2015) Targets for adjunctive therapy in pneu-
mococcal meningitis. J Neuroimmunol 278:262–270. https ://doi.
org/10.1016/j.jneur oim.2014.11.015
 4. Beardsley J, Wolbers M, Kibengo FM, Ggayi A-BM, Kamali A, 
Cuc NTK et al (2016) Adjunctive dexamethasone in HIV-associ-
ated cryptococcal meningitis. N Engl J Med 374:542–554. https 
://doi.org/10.1056/NEJMo a1509 024
 5. Bergmann S, Hammerschmidt S (2006) Versatility of pneumo-
coccal surface proteins. Microbiology 152:295–303. https ://doi.
org/10.1099/mic.0.28610 -0
 6. Brouwer MC, Meijers JCM, Baas F, van der Ende A, Pfister H-W, Giese 
A et al (2014) Plasminogen activator inhibitor-1 influences cerebrovas-
cular complications and death in pneumococcal meningitis. Acta Neu-
ropathol 127:553–564. https ://doi.org/10.1007/s0040 1-013-1216-4
 7. Coureuil M, Lecuyer H, Scott MGH, Boularan C, Enslen H, Soyer 
M et al (2010) Meningococcus Hijacks a beta2-adrenoceptor/beta-
Arrestin pathway to cross brain microvasculature endothelium. 
Cell 143:1149–1160. https ://doi.org/10.1016/j.cell.2010.11.035
 8. Czupalla CJ, Liebner S, Devraj K (2014) In vitro models of the 
blood-brain barrier. Methods Mol Biol 1135:415–437. https ://doi.
org/10.1007/978-1-4939-0320-7_34
 9. Davis MPA, van Dongen S, Abreu-Goodger C, Bartonicek N, 
Enright AJ (2013) Kraken: a set of tools for quality control and 
analysis of high-throughput sequence data. Methods 63:41–49. 
https ://doi.org/10.1016/j.ymeth .2013.06.027
 10. de Gans J, van de Beek D (2002) Dexamethasone in adults with 
bacterial meningitis. N Engl J Med 347:1549–1556. https ://doi.
org/10.1056/NEJMo a0213 34
 11. De Palma M, Biziato D, Petrova TV (2017) Microenvironmental 
regulation of tumour angiogenesis. Nat Rev Cancer 17:457–474. 
https ://doi.org/10.1038/nrc.2017.51
 12. Devraj K, Klinger ME, Myers RL, Mokashi A, Hawkins RA, 
Simpson IA (2011) GLUT-1 glucose transporters in the blood-
brain barrier: differential phosphorylation. J Neurosci Res 
89:1913–1925. https ://doi.org/10.1002/jnr.22738 
 13. Devraj K, Poznanovic S, Spahn C, Schwall G, Harter PN, Mit-
telbronn M et al (2016) BACE-1 is expressed in the blood-brain 
barrier endothelium and is upregulated in a murine model of Alz-
heimer’s disease. J Cereb Blood Flow Metab 36:1281–1294. https 
://doi.org/10.1177/02716 78X15 60646 3
 14. Devraj G, Beerlage C, Brune B, Kempf VAJ (2017) Hypoxia and 
HIF-1 activation in bacterial infections. Microbes Infect 19:144–
156. https ://doi.org/10.1016/j.micin f.2016.11.003
 15. Devraj K, Guerit S, Macas J, Reiss Y (2018) An in vivo blood-
brain barrier permeability assay in mice using fluorescently 
labeled tracers. J Vis Exp. https ://doi.org/10.3791/57038 
 16. Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, 
Steinbach JP et al (2019) Tumor vessel normalization, immu-
nostimulatory reprogramming, and improved survival in glio-
blastoma with combined inhibition of PD-1, angiopoietin-2, 
and VEGF. Cancer Immunol Res 7:1910–1927. https ://doi.
org/10.1158/2326-6066.CIR-18-0865
 17. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S 
et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinfor-
matics 29:15–21. https ://doi.org/10.1093/bioin forma tics/bts63 5
 18. Doran KS, Fulde M, Gratz N, Kim BJ, Nau R, Prasadarao N 
et al (2016) Host-pathogen interactions in bacterial meningitis. 
Acta Neuropathol 131:185–209. https ://doi.org/10.1007/s0040 
1-015-1531-z
 19. Dubinski D, Won S-Y, Gessler F, Quick-Weller J, Behmanesh B, 
Bernatz S et al (2018) Dexamethasone-induced leukocytosis is asso-
ciated with poor survival in newly diagnosed glioblastoma. J Neu-
rooncol 137:503–510. https ://doi.org/10.1007/s1106 0-018-2761-4
 20. Dubinski D, Hattingen E, Senft C, Seifert V, Peters KG, Reiss 
Y et al (2019) Controversial roles for dexamethasone in glio-
blastoma—opportunities for novel vascular targeting thera-
pies. J Cereb Blood Flow Metab 39:1460–1468. https ://doi.
org/10.1177/02716 78X19 85984 7
 21. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms 
of anti-tumour activity. Nat Rev Cancer 8:579–591. https ://doi.
org/10.1038/nrc24 03
 22. Engelen-Lee J-Y, Brouwer MC, Aronica E, van de Beek D (2016) 
Pneumococcal meningitis: clinical-pathological correlations 
(MeninGene-Path). Acta Neuropathol Commun 4:26. https ://doi.
org/10.1186/s4047 8-016-0297-4
 23. Engelhardt S, Al-Ahmad AJ, Gassmann M, Ogunshola OO (2014) 
Hypoxia selectively disrupts brain microvascular endothelial tight 
junction complexes through a hypoxia-inducible factor-1 (HIF-1) 
dependent mechanism. J Cell Physiol 229:1096–1105. https ://doi.
org/10.1002/jcp.24544 
 24. Feldman C, Anderson R (2014) Recent advances in our under-
standing of Streptococcus pneumoniae infection. F1000 Prime 
Rep 6:82. https ://doi.org/10.12703 /P6-82
 25. Gavard J, Gutkind JS (2006) VEGF controls endothelial-cell 
permeability by promoting the beta-arrestin-dependent endo-
cytosis of VE-cadherin. Nat Cell Biol 8:1223–1234. https ://doi.
org/10.1038/ncb14 86
 26. Gavard J, Patel V, Gutkind JS (2008) Angiopoietin-1 prevents 
VEGF-induced endothelial permeability by sequestering Src 
through mDia. Dev Cell 14:25–36. https ://doi.org/10.1016/j.devce 
l.2007.10.019
 27. Gurnik S, Devraj K, Macas J, Yamaji M, Starke J, Scholz A et al 
(2016) Angiopoietin-2-induced blood-brain barrier compromise 
and increased stroke size are rescued by VE-PTP-dependent res-
toration of Tie2 signaling. Acta Neuropathol 131:753–773. https 
://doi.org/10.1007/s0040 1-016-1551-3
 28. Hartmann H, Eltzschig HK, Wurz H, Hantke K, Rakin A, Yazdi 
AS et al (2008) Hypoxia-independent activation of HIF-1 by 
enterobacteriaceae and their siderophores. Gastroenterology 
134:756–767. https ://doi.org/10.1053/j.gastr o.2007.12.008
 29. Heide EC, Bindila L, Post JM, Malzahn D, Lutz B, Seele J et al (2018) 
Prophylactic palmitoylethanolamide prolongs survival and decreases 
detrimental inflammation in aged mice with bacterial meningitis. 
Front Immunol 9:2671. https ://doi.org/10.3389/fimmu .2018.02671 
 30. Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment 
in patients with brain metastases and primary brain tumors: do 
the benefits outweigh the side-effects? Support care cancer Off 
J Multinatl Assoc Support Care Cancer 10:322–328. https ://doi.
org/10.1007/s0052 0-001-0333-0
207Acta Neuropathologica (2020) 140:183–208 
1 3
 31. Hess N, Waldow F, Kohler TP, Rohde M, Kreikemeyer B, Gomez-
Mejia A et al (2017) Lipoteichoic acid deficiency permits normal 
growth but impairs virulence of Streptococcus pneumoniae. Nat 
Commun 8:2093. https ://doi.org/10.1038/s4146 7-017-01720 -z
 32. Hupp S, Ribes S, Seele J, Bischoff C, Fortsch C, Maier E et al 
(2017) Magnesium therapy improves outcome in Streptococcus 
pneumoniae meningitis by altering pneumolysin pore forma-
tion. Br J Pharmacol 174:4295–4307. https ://doi.org/10.1111/
bph.14027 
 33. Iovino F, Seinen J, Henriques-Normark B, van Dijl JM (2016) 
How does Streptococcus pneumoniae invade the brain? 
Trends Microbiol 24:307–315. https ://doi.org/10.1016/j.
tim.2015.12.012
 34. Iovino F, Engelen-Lee J-Y, Brouwer M, van de Beek D, van der 
Ende A, Valls Seron M et al (2017) pIgR and PECAM-1 bind to 
pneumococcal adhesins RrgA and PspC mediating bacterial brain 
invasion. J Exp Med 214:1619–1630. https ://doi.org/10.1084/
jem.20161 668
 35. Kempf VA, Volkmann B, Schaller M, Sander CA, Alitalo K, Riess 
T et al (2001) Evidence of a leading role for VEGF in Bartonella 
henselae-induced endothelial cell proliferations. Cell Microbiol 
3:623–632. https ://doi.org/10.1046/j.1462-5822.2001.00144 .x
 36. Kempf VAJ, Lebiedziejewski M, Alitalo K, Walzlein J-H, Ehehalt 
U, Fiebig J et al (2005) Activation of hypoxia-inducible factor-1 in 
bacillary angiomatosis: evidence for a role of hypoxia-inducible 
factor-1 in bacterial infections. Circulation 111:1054–1062. https 
://doi.org/10.1161/01.CIR.00001 55608 .07691 .B7
 37. Kestner R, Mayser F, Vutukuri R, Hansen L, Günther S, Brunk-
horst R et al (2020) Gene expression dynamics at the neurovascu-
lar unit during early regeneration after cerebral ischemia/reperfu-
sion injury in mice. Front Neurosci 2020:14
 38. Kim KS (2008) Mechanisms of microbial traversal of the 
blood-brain barrier. Nat Rev Microbiol 6:625–634. https ://doi.
org/10.1038/nrmic ro195 2
 39. Kim BJ, Hancock BM, Bermudez A, Del Cid N, Reyes E, van 
Sorge NM et al (2015) Bacterial induction of Snail1 contributes 
to blood-brain barrier disruption. J Clin Invest 125:2473–2483. 
https ://doi.org/10.1172/JCI74 159
 40. Kjos M, Aprianto R, Fernandes VE, Andrew PW, van Strijp JAG, 
Nijland R et al (2015) Bright fluorescent Streptococcus pneumo-
niae for live-cell imaging of host-pathogen interactions. J Bacte-
riol 197:807–818. https ://doi.org/10.1128/JB.02221 -14
 41. Klein M, Koedel U, Pfister H-W (2006) Oxidative stress in pneu-
mococcal meningitis: a future target for adjunctive therapy? 
Prog Neurobiol 80:269–280. https ://doi.org/10.1016/j.pneur 
obio.2006.11.008
 42. Koedel U, Frankenberg T, Kirschnek S, Obermaier B, Hacker 
H, Paul R et al (2009) Apoptosis is essential for neutrophil func-
tional shutdown and determines tissue damage in experimental 
pneumococcal meningitis. PLoS Pathog 5:e1000461. https ://doi.
org/10.1371/journ al.ppat.10004 61
 43. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, 
Monks A et al (2005) Echinomycin, a small-molecule inhibitor 
of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 
65:9047–9055. https ://doi.org/10.1158/0008-5472.CAN-05-1235
 44. Koto T, Takubo K, Ishida S, Shinoda H, Inoue M, Tsubota K et al 
(2007) Hypoxia disrupts the barrier function of neural blood ves-
sels through changes in the expression of claudin-5 in endothelial 
cells. Am J Pathol 170:1389–1397. https ://doi.org/10.2353/ajpat 
h.2007.06069 3
 45. Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient gen-
eral purpose program for assigning sequence reads to genomic 
features. Bioinformatics 30:923–930. https ://doi.org/10.1093/
bioin forma tics/btt65 6
 46. Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Con-
stantin G (2018) Functional morphology of the blood-brain barrier 
in health and disease. Acta Neuropathol 135:311–336. https ://doi.
org/10.1007/s0040 1-018-1815-1
 47. Liu T, Ma W, Xu H, Huang M, Zhang D, He Z et al (2018) 
PDGF-mediated mesenchymal transformation renders endothelial 
resistance to anti-VEGF treatment in glioblastoma. Nat Commun 
9:3439. https ://doi.org/10.1038/s4146 7-018-05982 -z
 48. Love MI, Huber W, Anders S (2014) Moderated estimation of fold 
change and dispersion for RNA-seq data with DESeq2. Genome 
Biol 15:550. https ://doi.org/10.1186/s1305 9-014-0550-8
 49. Lucas MJ, Brouwer MC, van de Beek D (2016) Neurological 
sequelae of bacterial meningitis. J Infect 73:18–27. https ://doi.
org/10.1016/j.jinf.2016.04.009
 50. Machein MR, Kullmer J, Ronicke V, Machein U, Krieg M, Damert 
A et al (1999) Differential downregulation of vascular endothe-
lial growth factor by dexamethasone in normoxic and hypoxic rat 
glioma cells. Neuropathol Appl Neurobiol 25:104–112. https ://
doi.org/10.1046/j.1365-2990.1999.00166 .x
 51. Mark KS, Davis TP (2002) Cerebral microvascular changes in per-
meability and tight junctions induced by hypoxia-reoxygenation. 
Am J Physiol Heart Circ Physiol 282:H1485–H1494. https ://doi.
org/10.1152/ajphe art.00645 .2001
 52. McGill F, Heyderman RS, Panagiotou S, Tunkel AR, Solomon T 
(2016) Acute bacterial meningitis in adults. Lancet (Lond, Engl) 
388:3036–3047. https ://doi.org/10.1016/S0140 -6736(16)30654 -7
 53. Nguyen THM, Tran THC, Thwaites G, Ly VC, Dinh XS, Ho Dang 
TN et al (2007) Dexamethasone in Vietnamese adolescents and 
adults with bacterial meningitis. N Engl J Med 357:2431–2440. 
https ://doi.org/10.1056/NEJMo a0708 52
 54. Oordt-Speets AM, Bolijn R, van Hoorn RC, Bhavsar A, Kyaw 
MH (2018) Global etiology of bacterial meningitis: a systematic 
review and meta-analysis. PLoS ONE 13:e0198772. https ://doi.
org/10.1371/journ al.pone.01987 72
 55. Park Y-S, Shin W-S, Kim S-K (2008) In vitro and in vivo activities 
of echinomycin against clinical isolates of Staphylococcus aureus. 
J Antimicrob Chemother 61:163–168. https ://doi.org/10.1093/jac/
dkm42 1
 56. Pracht D, Elm C, Gerber J, Bergmann S, Rohde M, Seiler M et al 
(2005) PavA of Streptococcus pneumoniae modulates adherence, 
invasion, and meningeal inflammation. Infect Immun 73:2680–
2689. https ://doi.org/10.1128/IAI.73.5.2680-2689.2005
 57. Ramilo O, Saez-Llorens X, Mertsola J, Jafari H, Olsen KD, 
Hansen EJ et al (1990) Tumor necrosis factor alpha/cachectin and 
interleukin 1 beta initiate meningeal inflammation. J Exp Med 
172:497–507. https ://doi.org/10.1084/jem.172.2.497
 58. Rennemeier C, Hammerschmidt S, Niemann S, Inamura S, Zah-
ringer U, Kehrel BE (2007) Thrombospondin-1 promotes cellular 
adherence of gram-positive pathogens via recognition of pepti-
doglycan. FASEB J Off Publ Fed Am Soc Exp Biol 21:3118–
3132. https ://doi.org/10.1096/fj.06-7992c om
 59. Riess T, Andersson SGE, Lupas A, Schaller M, Schafer A, Kyme 
P et al (2004) Bartonella adhesin a mediates a proangiogenic host 
cell response. J Exp Med 200:1267–1278. https ://doi.org/10.1084/
jem.20040 500
 60. Ring A, Weiser JN, Tuomanen EI (1998) Pneumococcal traffick-
ing across the blood-brain barrier. Molecular analysis of a novel 
bidirectional pathway. J Clin Invest 102:347–360. https ://doi.
org/10.1172/JCI24 06
 61. Rohnelt RK, Hoch G, Reiss Y, Engelhardt B (1997) Immunosur-
veillance modelled in vitro: naive and memory T cells spontane-
ously migrate across unstimulated microvascular endothelium. Int 
Immunol 9:435–450. https ://doi.org/10.1093/intim m/9.3.435
 62. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit 
JM et al (2000) Hypoxia-inducible factor-1alpha is a positive fac-
tor in solid tumor growth. Cancer Res 60:4010–4015
 63. Scarborough M, Gordon SB, Whitty CJM, French N, Njalale Y, 
Chitani A et al (2007) Corticosteroids for bacterial meningitis in 
208 Acta Neuropathologica (2020) 140:183–208
1 3
adults in sub-Saharan Africa. N Engl J Med 357:2441–2450. https 
://doi.org/10.1056/NEJMo a0657 11
 64. Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji 
M et al (2016) Endothelial cell-derived angiopoietin-2 is a thera-
peutic target in treatment-naive and bevacizumab-resistant glio-
blastoma. EMBO Mol Med 8:39–57. https ://doi.org/10.15252 /
emmm.20150 5505
 65. Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K et al 
(2014) Targeting VE-PTP activates TIE2 and stabilizes the ocular 
vasculature. J Clin Invest 124:4564–4576. https ://doi.org/10.1172/
JCI74 527
 66. Shields LBE, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons 
S et al (2015) Dexamethasone administration during definitive 
radiation and temozolomide renders a poor prognosis in a retro-
spective analysis of newly diagnosed glioblastoma patients. Radiat 
Oncol 10:222. https ://doi.org/10.1186/s1301 4-015-0527-0
 67. Tsai JM, Sinha R, Seita J, Fernhoff N, Christ S, Koopmans T et al 
(2018) Surgical adhesions in mice are derived from mesothelial 
cells and can be targeted by antibodies against mesothelial markers. 
Sci Transl Med. https ://doi.org/10.1126/scitr anslm ed.aan67 35
 68. Tsao N, Chang WW, Liu CC, Lei HY (2002) Development of 
hematogenous pneumococcal meningitis in adult mice: the role 
of TNF-alpha. FEMS Immunol Med Microbiol 32:133–140. https 
://doi.org/10.1111/j.1574-695X.2002.tb005 45.x
 69. Uchiyama S, Carlin AF, Khosravi A, Weiman S, Banerjee A, 
Quach D et al (2009) The surface-anchored NanA protein pro-
motes pneumococcal brain endothelial cell invasion. J Exp Med 
206:1845–1852. https ://doi.org/10.1084/jem.20090 386
 70. Uliasz TF, Hamby ME, Jackman NA, Hewett JA, Hewett SJ 
(2012) Generation of primary astrocyte cultures devoid of con-
taminating microglia. Methods Mol Biol 814:61–79. https ://doi.
org/10.1007/978-1-61779 -452-0_5
 71. van de Beek D, Farrar JJ, de Gans J, Mai NTH, Molyneux EM, 
Peltola H et al (2010) Adjunctive dexamethasone in bacterial men-
ingitis: a meta-analysis of individual patient data. Lancet Neurol 
9:254–263. https ://doi.org/10.1016/S1474 -4422(10)70023 -5
 72. van der Flier M, Stockhammer G, Vonk GJ, Nikkels PG, van 
Diemen-Steenvoorde RA, van der Vlist GJ et al (2001) Vascu-
lar endothelial growth factor in bacterial meningitis: detection in 
cerebrospinal fluid and localization in postmortem brain. J Infect 
Dis 183:149–153. https ://doi.org/10.1086/31764 3
 73. Wang Y, Liu Y, Tang F, Bernot KM, Schore R, Marcucci G 
et al (2014) Echinomycin protects mice against relapsed acute 
myeloid leukemia without adverse effect on hematopoietic stem 
cells. Blood 124:1127–1135. https ://doi.org/10.1182/blood -2013-
12-54422 1
 74. Wellmer A, Gerber J, Ragheb J, Zysk G, Kunst T, Smirnov A 
et al (2001) Effect of deficiency of tumor necrosis factor alpha or 
both of its receptors on Streptococcus pneumoniae central nerv-
ous system infection and peritonitis. Infect Immun 69:6881–6886. 
https ://doi.org/10.1128/IAI.69.11.6881-6886.2001
 75. Werth N, Beerlage C, Rosenberger C, Yazdi AS, Edelmann M, 
Amr A et al (2010) Activation of hypoxia inducible factor 1 is a 
general phenomenon in infections with human pathogens. PLoS 
ONE 5:e11576. https ://doi.org/10.1371/journ al.pone.00115 76
 76. Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S et al (2011) 
KOBAS 2.0: a web server for annotation and identification of 
enriched pathways and diseases. Nucleic Acids Res 39:W316–
W322. https ://doi.org/10.1093/nar/gkr48 3
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
Affiliations
Gayatri Devraj1 · Sylvaine Guérit2 · Jana Seele3,4 · Daniel Spitzer2,5 · Jadranka Macas2 · Maryam I. Khel2 · 
Roxana Heidemann3 · Anne K. Braczynski2,6 · Wibke Ballhorn1 · Stefan Günther7 · Omolara O. Ogunshola8 · 
Michel Mittelbronn2,9,10,11,12 · Uwe Ködel13 · Camelia M. Monoranu14 · Karl H. Plate2,15 · Sven Hammerschmidt16 · 
Roland Nau3 · Kavi Devraj2,15 · Volkhard A. J. Kempf1 
 Gayatri Devraj 
 Gayatri.Devraj@kgu.de
1 Institute for Medical Microbiology and Infection Control, 
Goethe University, Frankfurt am Main, Germany
2 Edinger Institute/Neurological Institute, Goethe University, 
Frankfurt am Main, Germany
3 Institute of Neuropathology, University Medical Center, 
Göttingen, Germany
4 Department of Geriatrics, Evangelisches Krankenhaus, 
Göttingen-Weende, Germany
5 Department of Neurology, Goethe University, 
Frankfurt am Main, Germany
6 Department of Neurology, Technische Hochschule University 
Hospital, Aachen, Germany
7 Max Planck Institute for Heart and Lung Research, 
Bad Nauheim, Germany
8 Institute of Veterinary Physiology, University of Zurich, 
Zurich, Switzerland
9 Luxembourg Centre of Neuropathology (LCNP), 
Luxembourg, Luxembourg
10 Laboratoire National de Santé (LNS), Dudelange, 
Luxembourg
11 Luxembourg Centre for Systems Biomedicine (LCSB), 
University of Luxembourg, Luxembourg, Luxembourg
12 NORLUX Neuro-Oncology Laboratory, Luxembourg 
Institute of Health (LIH), Luxembourg, Luxembourg
13 Department of Neurology, Ludwig-Maximilians University, 
Munich, Germany
14 Department of Neuropathology, Institute of Pathology, Julius 
Maximilians University, Würzburg, Germany
15 Frankfurt Cancer Institute (FCI), Goethe University, 
Frankfurt am Main, Germany
16 Department of Molecular Genetics and Infection Biology, 
Interfaculty Institute for Genetics and Functional Genomics, 
Center for Functional Genomics of Microbes, University 
of Greifswald, Greifswald, Germany
